6DQRIL3DVWHXU 0(7
Â±0HQ$&<:&RQMXJDWH9DFFLQH
&RQILGHQWLDO3URSULHWDU\,QIRUPDWLRQ
3DJHRI,PPXQH/RW&RQVLVWHQF\,PPXQRJHQLFLW\DQG6DIHW\RIDQ
,QYHVWLJDWLRQDO4XDGULYDOHQW0HQLQJRFRFFDO&RQMXJDWH9DFFLQH
LQ$GROHVFHQWVDQG$GXOWV$JHGWR<HDUV
3KDVH,,,PRGLILHGGRXEOHEOLQGUDQGRPL]HGSDUDOOHOJURXSD FWLYHFRQWUROOHGPXOWLFHQWHU
VWXG\WRHYDOXDWHLPPXQHORWFRQ VLVWHQF\RI0HQ$&<:FRQMXJDWHY DFFLQHHYDOXDWHWKH
LPPXQHQRQLQIHULRULW\YHUVXV0HQDFWUDÂŠDQGGHVFULEHWKHVDIHW\DQGDGGLWLRQDO
LPPXQRJHQLFLW\RIWKH VHVWXG\YDFFLQHVLQDGROH VFHQWVDQGDGXOW VDJHGWR\HDUVLQWKH
8QLWHG6WDWHV 

&OLQLFDO7ULDO3URWRFRO$PHQGPHQW

+HDOWK$XWKRULW\)LOH1XPEHU %%,1' 
:+28QLYHUVDO7ULDO1XPEHU
8718
7ULDO&RGH 0(7
'HYHORSPHQW3KDVH 3KDVH,,,
6SRQVRU 6DQRIL3DVWHXU,QF
'LVFRYHU\'ULYH6ZLIWZDWHU3$86$
,QYHVWLJDWLRQDO3URGXFW 0HQ$&<:FRQMXJDWHYDFFLQH 0HQLQJRFRFFDO3RO\VDFFKDULGH
6HURJURXSV$&< DQG:7HWD QXV7R[RLG&R QMXJDWH9DFFLQH 
)RUP5RXWH /LTXLG6ROXWLRQ,QWUDPXVFXODU
,QGLFDWLRQ)RU7KLV6WXG\ 0HQ$&<:FRQMXJDWHYDFFLQHDVD VLQJOHGRVHLQDGROHVFHQWVDQGD GXOWV
DJHGWR\HDUV
0DQXIDFWXUHU 6DPHDV6SRQVRU
&RRUGLQDWLQJ,QYHVWLJDWRU  

6SRQVRUÂ¶V5HVSRQVLEOH0HGLFDO
2IILFHU
6DQRIL3DVWHXU,QF
7HO
)D[
3URGXFW6DIHW\2IILFHU 
6DQRIL3DVWHXU,QF
7HO
)D[
&OLQLFDO7ULDO0DQDJHU 
6DQRIL3DVWHXU,QF
7HO 
9HUVLRQDQG'DWHRIWKH3URWRFRO 9HUVLRQGDWHG-XQH 
7KLVSURWRFROYHUVLRQLVWKHILUVWDPHQGPHQWWRWKHLQLWLDO WULDOSURWRFROYHUVLRQGDWHG-DQXDU\
,QIRUPDWLRQFRQWDLQHGLQWKLVSXE OLFDWLRQLVWKHSURSHUW\RI6D QRIL3DVWHXUDQGLVFRQILGHQWLDO 7KLVLQIRUPDWLRQPD\QRWEH
GLVFORVHGWRWKLUGSDUWLHVZLWK RXWZULWWHQDXWKRUL]DWLRQIURP6 DQRIL3DVWHXU7KLVGRFXPHQWPD\ QRWEHUHSURGXFHGVWRUHGLQD 
UHWULHYDOV\VWHPRUWUDQVPLWWHG LQDQ\IRUPRUE\DQ\PHDQVÂ±HO HFWURQLFPHFKDQLFDOUHFRUGLQJ RURWKHUZLVHÂ±ZLWKRXWSULRU
DXWKRUL]DWLRQIURP6DQRIL3DVWHXU 7KLVGRFXPHQWPXVWEHUHWXUQ HGWR6DQRIL3DVWHXUXSRQUHTXHVW 
6DQRIL3DVWHXU 

&RQILGHQWLDO3URSULHWDU\,QIRUPDWLRQ
0(7
Â±0HQ$&<:&RQMXJDWH9DFFLQH 3URWRFRO9HUVLRQ
3DJHRI/$5/VNCFS/$5
PI[INVESTIGATOR_394273]43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page [ADDRESS_494775] ..................................................................... 23  
1.2.1  Non-clinical Safety  ....................................................................................................... 23  
1.2.2  Clinical  ......................................................................................................................... 23  
[IP_ADDRESS]  Study MET39 (Phase II) ............................................................................................ 24  
[IP_ADDRESS]  Study MET44 (Phase II) ............................................................................................ 25  
1.3 Potential Benefits and Risks ........................................................................................... 25  
1.3.1  Potential Benefits to Subjects  ....................................................................................... 25  
1.3.2  Potential Risks to Subjects ........................................................................................... 26  
1.4 Rationale for the Trial ..................................................................................................... 27  
2 Trial Objectives  ............................................................................................................... 28  
2.1 Primary Objectives  .......................................................................................................... 28  
2.2 Secondary Objectives  ...................................................................................................... 28  
2.3 Observational Objectives  ................................................................................................ 28  
3 Investigators and Trial Organization ............................................................................ 29  
4 Independent Ethics Committee / Institutional Review Board  .................................... 29  
5 Investigational Plan  ......................................................................................................... 30  
5.1 Description of the Overall Trial Design and Plan ........................................................... 30  
5.1.1  Trial Design  .................................................................................................................. 30  
5.1.2  Justification of the Trial Design  ................................................................................... 30  
5.1.3  Trial Plan  ...................................................................................................................... 31  
5.1.4  Visit Procedures  ............................................................................................................ 32  
5.1.5  Planned Trial Calendar ................................................................................................. 34  
5.1.6  Early Safety Data Review ............................................................................................. 34 
5.2 Enrollment and Retention of Trial Population ................................................................ 35  
5.2.1  Recruitment Procedures  ................................................................................................ 35  
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 2 of 80
[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page [ADDRESS_494776] ............................................................................................... 41  
[IP_ADDRESS]  Composition  ............................................................................................................... 42  
[IP_ADDRESS]  Preparation and Administration  ................................................................................. 42  
[IP_ADDRESS]  Dose Selection and Timing ........................................................................................ [ADDRESS_494777] ........................................................................................... 42  
[IP_ADDRESS]  Composition  ............................................................................................................... 43  
[IP_ADDRESS]  Preparation and Administration  ................................................................................. 43  
[IP_ADDRESS]  Dose Selection and Timing ........................................................................................ [ADDRESS_494778] Shipment, Storage, and Accountability ........................................................... 44  
[IP_ADDRESS]  Product Shipment ....................................................................................................... 44  
[IP_ADDRESS]  Product Storage .......................................................................................................... 44  
[IP_ADDRESS]  Product Accountability ............................................................................................... 44  
6.3.3  Replacement Doses ....................................................................................................... 44 
6.3.4  Disposal of Unused Products ........................................................................................ 45  
6.3.5  Recall of Products ......................................................................................................... 45  
6.4 Blinding and Code-breaking Procedures ........................................................................ 45  
6.5 Randomization and Allocation Procedures ..................................................................... 45  
6.6 Treatment Compliance  .................................................................................................... 46  
6.7 Concomitant Medications and Other Therapi[INVESTIGATOR_014]  ............................................................. 46  
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 3 of 80
[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 4 of 79 7 Management of Samples ................................................................................................. 47  
7.1 Sample Collection  ........................................................................................................... 47  
7.2 Sample Preparation  ......................................................................................................... 48  
7.3 Sample Storag e and Shipment ........................................................................................ 48  
7.4 Future Use of Stored Serum Samples for Research  ........................................................ 48  
8 Clinical Supplies  .............................................................................................................. 49  
9 Endpoints and Assessment Methods  ............................................................................. 49  
9.1 Primary Endpoints and Assessment Methods ................................................................. 49  
9.1.1  Immu nogenicity ............................................................................................................ 49  
[IP_ADDRESS]  Immunogenicity Endpoints ........................................................................................ 49  
[IP_ADDRESS]  Immunogenicity Assessment Method ........................................................................ 50  
9.1.2  Safety  ............................................................................................................................ 50  
9.1.3  Efficacy  ......................................................................................................................... 50  
9.2 Secondary Endpoints and Assessment Methods ............................................................. 50  
9.2.1  Immunogenicity ............................................................................................................ 50  
[IP_ADDRESS]  Immunogenicity Endpoints ........................................................................................ 50  
[IP_ADDRESS]  Immunogeni city Assessment Methods ...................................................................... 51  
9.2.2  Safety  ............................................................................................................................ 51  
9.2.3  Efficacy  ......................................................................................................................... 51  
9.3 Observational Endpoints and Assessment Methods ....................................................... 51  
9.3.1  Immunogenicity ............................................................................................................ 51  
[IP_ADDRESS]  Immunogenicity Endpoints ........................................................................................ 51  
[IP_ADDRESS]  Immunogenicity Assessment Method ........................................................................ 51  
9.3.2  Safety  ............................................................................................................................ 52  
[IP_ADDRESS]  Safety Defini tions ....................................................................................................... 52  
[IP_ADDRESS]  Safety Endpoints ........................................................................................................ 55  
[IP_ADDRESS]  Safety Assessment Methods ....................................................................................... 55  
[IP_ADDRESS].[ADDRESS_494779] -vaccination Surveillance Period .................................................... 55  
[IP_ADDRESS].2  Reactogenicity (Solicited Reactions From Day 0 to Day 07 After 
Vaccination)  ............................................................................................................. 56  
[IP_ADDRESS].3  Unsolicited Non- serious Adverse Events From Day  0 to Day 30 After 
Vaccination  .............................................................................................................. 59  
[IP_ADDRESS].4  Serious Adverse Events  ........................................................................................... 60  
  
[IP_ADDRESS].6  Medically -Attended Adverse Events  ....................................................................... 60  
[IP_ADDRESS].7  Assessment of Causality  .......................................................................................... 60  
9.3.3  Efficacy  ......................................................................................................................... 61  
10 Reporting of Serious Adverse Events ............................................................................ 61  
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 4 of 80

[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page [ADDRESS_494780] Has Completed the Study ...................... 62  
10.4  Assessment of Causality  ................................................................................................. 62  
10.5  Reporting SAEs to H ealth Authorities and IECs / IRBs ................................................. 63  
11 Data Collection and Management ................................................................................. 63  
11.1  Data Collection and CRF Completion ............................................................................ 63  
11.2  Data Management  ........................................................................................................... 64  
11.3  Data Review  .................................................................................................................... 65  
12 Statistical Methods and Determination of Sample Size  ............................................... 65  
12.1  Statistical Methods  .......................................................................................................... 65  
12.1.1  Hypotheses and Statistical Methods for Primary Objectives  ....................................... 65  
[IP_ADDRESS]  Primary Objective 1  ................................................................................................... 65  
[IP_ADDRESS]  Primary Objective 2  ................................................................................................... 66  
12.1.2  Hypotheses and Statistical Methods for Secondary Objectives  ................................... 67  
[IP_ADDRESS]  Secondary Objective 1  ............................................................................................... 67  
[IP_ADDRESS]  Secondary Objective  2 ............................................................................................... 67  
[IP_ADDRESS]  Secondary Objective 3  ............................................................................................... 68  
[IP_ADDRESS]  Secondary Objective 4  ............................................................................................... 68  
12.1.3  Statistical Methods for Observational Objectives  ........................................................ 68  
[IP_ADDRESS]  Immunogenicity ......................................................................................................... 68  
[IP_ADDRESS]  Safety  .......................................................................................................................... 69  
12.2  Analysis Sets ................................................................................................................... 69  
12.2.1  Full Analysis Set ........................................................................................................... 70  
12.2.2  Safety Analysis Set  ....................................................................................................... 70  
12.2.3  Per-Protocol Analysis Set ............................................................................................. 70  
12.2.4  Populations Used in Analyses ...................................................................................... 70  
12.3  Handling of Missing Data and Outliers .......................................................................... 71  
12.3.1  Safety  ............................................................................................................................ 71  
12.3.2  Immunogenicity ............................................................................................................ 71  
12.3.3  Efficacy  ......................................................................................................................... 71  
12.4  Interim / Preliminary Analysis  ........................................................................................ 71  
12.5  Determination of Sample Siz e and Power Calculation  ................................................... 71  
13 Ethical and Legal Issues and Investigator / Sponsor Responsibilities ........................ [ADDRESS_494781] of the Trial / Good Clinical Practice  .................................................... 72  
13.2  Source Data and Source Documents ............................................................................... 73  
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 5 of 80
[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page [ADDRESS_494782] ................................................................................................................. 76  
15 Signature [CONTACT_68615]  ............................................................................................................... 79  
 
 
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 6 of 80
[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page [ADDRESS_494783] of Tables  
Table 9.1: Solicited injection site reactions: terminology, definitions, and intensity scales  ...........57  
Table 9.2: Solicited systemic reactions: terminology, definitions, and int ensity scales .................58  
Table 12.1: Power of the study based on Primary Objective 1 of equivalence ...............................72  
Table 12.2: Power of the study based on Primary Objective 2 of non- inferiority  ..........................72  
 
 
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 7 of 80
6DQRIL3DVWHXU 0(7
Â±0HQ$&<:&RQMXJDWH9DFFLQH
&RQILGHQWLDO3URSULHWDU\,QIRUPDWLRQ
3DJHRI6\QRSVLV

&RPSDQ\ 6DQRIL3DVWHXU
,QYHVWLJDWLRQDO3URGXFW 0HQ$&<:FRQMXJDWHYDFFLQH 
$FWLYH6XEVWDQFHV &DSVXODUSRO\VDFFKDULGHIURPPHQ LQJRFRFFDOVHURJURXSV$&< DQG:
FRQMXJDWHGWRWHWDQXVWR[RLG 
7LWOHRIWKH7ULDO ,PPXQH/RW&RQVLVWHQF\,PPXQRJH QLFLW\DQG6DIHW\RIDQ,QYHVW LJDWLRQDO
4XDGULYDOHQW0HQLQJRFRFFDO&RQMXJDWH9DFFLQHLQ$GROHVFHQWVDQG $GXOWV
$JHGWR<HDUV 
'HYHORSPHQW3KDVH 3KDVH,,,
&RRUGLQDWLQJ,QYHVWLJDWRU 

7ULDO&HQWHUV 7KLVZLOOEHDPXOWLFHQWHUWULDOFRQGXFWHGDWDSSUR[LPDWHO\ VLWHVLQWKH
8QLWHG6WDWHV
,QYHVWLJDWRUVDQGV LWHVDUHOLVWHGLQWKH Â³/LVWRI,QYHVWLJDWRU VDQG&HQWHUV
,QYROYHGLQWKH7U LDOÂ´GRFXPHQW
3ODQQHG7ULDO3HULRG 4WR4
7ULDO'HVLJQDQG0HWKRGRORJ\ 7KLVZLOOEHD3KDVH,,,PRGLILHGGRXEOHEOLQGUDQGRPL]HGSD UDOOHOJURXS
DFWLYHFRQWUROOHGPXOWLFHQWHUVWXG\WRHYDOXDWHLPPXQHORWFR QVLVWHQF\RI
0HQ$&<:FRQMXJDWHYDFFLQHHYDOX DWHWKHLPPXQHQRQLQIHULRULW\ YHUVXV
0HQDFWUDÂŠDQGGHVFULEHWKHVDIHW\DQGDGGLWLRQDOLPPXQRJHQLFLW\RIVWXG \
YDFFLQHVLQDGROHVFHQWVDQGDGX OWVDJHGWR\HDUVLQWKH8 6
$SSUR[LPDWHO\K HDOWK\PHQLQJR FRFFDOYDFFLQHQDwYHDGROHVF HQWVDQG
DGXOWVZLOOEHUDQGRPL]HGLQDUDWLRWRWKHIROORZLQJJ URXSV
x*URXS0HQ$&<:FRQMXJDWH YDFFLQH/RW
x*URXSDVXEMHFWV WR\HDUVRIDJH
x*URXSEVXEMHFWV WR\HDUVRIDJH
x*URXS0HQ$&<:FRQMXJDWH YDFFLQH/RW
x*URXSDVXEMHFWV WR\HDUVRIDJH
x*URXSEVXEMHFWV WR\HDUVRIDJH
x*URXS0HQ$&<:FRQMXJDWH YDFFLQH/RW
x*URXSDVXEMHFWVWR\HDUVRIDJH
x*URXSEVXEMHFWV WR\HDUVRIDJH
x*URXS0HQDFWUDÂŠ
x*URXSDVXEMHFWV WR\HDUVRIDJH
x*URXSEVXEMHFWVWR\HDUVRIDJH
 $OOVXEMHFWVZLOOSURYLGHEORRGVDPSOHVIRULPPXQRJHQLFLW\DVVH VVPHQWDW
EDVHOLQHSUHYDFFLQDWLRQDQGD WWRGD\VSRVWYDFFLQDWLR Q6ROLFLWHG
DGYHUVHHYHQW$(LQI RUPDWLRQZLOOEHFROOHFWHGIRUGD\VDIW HUYDFFLQDWLRQ
XQVROLFLWHG$(LQIRUPDWLRQZLOOEHFROOHFWHGIURP9LVLW'D\ >'@WR
9LVLW'>GD\V@DQGVHU LRXVDGYHUVHHYHQ W6$(LQIRU PDWLRQZLOO
EHFROOHFWHGIURP' WKURXJK' GD\VDIWHUYDFFLQDWLRQ 0HGLFDOO\
DWWHQGHGDGYHUVHHYHQWV0$$(V ZLOOEHFROOHFWHGWKURXJKRXWWK HVWXG\
IURP9LVLWWR9LVLWDVSDUW RIWKHFROOHFWLRQRIXQVROLFLW HG$(
LQIRUPDWLRQDQGIURP9LVLWWKURXJK'GD\VDV0$$(V 6DQRIL3DVWHXU 

&RQILGHQWLDO3URSULHWDU\,QIRUPDWLRQ
0(7
Â±0HQ$&<:&RQMXJDWH9DFFLQH 3URWRFRO9HUVLRQ
3DJHRIPII
PI[INVESTIGATOR_394274]43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 9 of 79 Early Safety Data Review:  This trial will not include an early review of safety data  (i.e., no early safety 
review[s] of preliminary safety data occurring at pre -determined milestones 
defined in the protocol with pause in enrollment) . However, it may be 
interrupted at any time if new data about the investigational product become 
available, and/or on advice of the Sponsor, the Independent Ethics 
Committees ( IECs ) / Institutional Review Boards ( IRBs ), or the  governing 
regulatory authorities in the country where the trial is taking place.  
If the trial is prematurely terminated or suspended, the Sponsor will promptly 
inform the Investigators, the IECs/IRBs, and the regulatory authorities of the reason for term ination or suspension. If the trial is prematurely terminated for 
any reason, the Investigator will promptly inform the trial subjects or the  
subjectsâ€™ parents / guardian and should assure appropriate therapy and follow -up. 
Primary Objectives:  1) To demonstr ate the immune lot consistency of the antibody responses 
to meningococcal serogroups A, C, Y, and W following the administration of a single dose of MenACYW conjugate vaccine with 
respect to serum bactericidal assay using human complement (hSBA) 
geometric mean titers (GMTs)  
2) To demonstrate the non -inferiority of the antibody responses to 
meningococcal serogroups A, C, Y, and W following the administration of a single dose of MenACYW conjugate vaccine 
(pooled Lots 1 to 3) compared to those observed following the 
administration of a single dose of Menactra
Â® 
Primary Endpoints: 1) Geometric mean titer ratios (GMTRs) of antibodies against 
meningococcal serogroups A, C, Y, and W measured by [CONTACT_357256] 30 days 
(+14  days) after vaccination between lots for immune lot consist ency  
2) Vaccine seroresponse of meningococcal serogroups A, C, Y, and W 
measured by [CONTACT_394281] (D0, before vaccination) and 30 days (+14  days) after vaccination for immune non -inferiority 
between MenACYW conjugate vaccine and Menactra
Â® (Groups  1 - 3 
pooled versus  Group  4) 
Secondary Objectives: 1) To demonstrate the non -inferiority of the antibody responses to 
meningococcal serogroups A, C, Y, and W following the 
administration of a single dose of MenACYW conjugate vaccine 
(pooled Lots 1 to 3) compared to those observed following the 
administration of a single dose of MenactraÂ® in the adult population 
(18 to 55  years old)  
2) To demonstrate the non -inferiority of the antibody responses to 
meningococcal serogroups A, C, Y, and W following the 
administrat ion of a single dose of MenACYW conjugate vaccine 
(pooled Lots 1 to 3) compared to those observed following the 
administration of a single dose of MenactraÂ® in the adolescent 
population (10 to 17 years old)  
3) To compare the hSBA vaccine seroresponses of meningococcal 
serogroups A, C, Y, and W for each of 3 lots of MenACYW conjugate vaccine 30  days (+14  days) after vaccination  
 4) To compare the hSBA antibody GMTs of meningococcal serogroups A, C, Y, and W following the administration of MenACYW conjugate 
vaccin e to those observed following the administration of Menactra
Â® 
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 9 of 80
[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 10 of 79 Secondary Endpoints:  1) Vaccine seroresponse of meningococcal serogroups A, C, Y, and W 
measured by [CONTACT_394281] (D0, before vaccination) and 
30 days (+14  days) after vaccination for immune non -inferiority 
between MenACYW conjugate vaccine and MenactraÂ® adult study 
participants (Groups  1b, 2b, and 3b pooled versus  Group  4b) 
2) Vaccine seroresponse of meningococcal serogroups A, C, Y, and W 
measured by [CONTACT_394281] (D0, before vaccination) and 
30 days (+14  days) after vaccination for immune non -inferiority 
between MenACYW conjugate vaccine and MenactraÂ® adolescent 
study participants (Groups  1a, 2a, and 3a pooled versus Group  4a) 
3) Vaccine seroresponse of meningococcal serogroups A, C, Y, and W 
measured by [CONTACT_357256] 30 days (+14 days) following the administration of 
MenACYW conjugate vaccine (Groups  1, 2, and 3)  
 4) GMTRs of antibodies against meningococcal serogroups A, C, Y, and 
W measured by [CONTACT_394282] (Groups  1 - 3 pooled) and Menactra
Â® (Group  4) 
Observational Objectives:  Immunogenicity 
To describe the antibody responses to the meningococcal serogroups A, C, 
Y, and W before and 30  days (+14  days) after vaccination with MenACYW 
conjugate  vaccine or MenactraÂ® 
Safety 
To describe the safety profi le of MenACYW conjugate vaccine  and that of 
the licensed  MenactraÂ® 
Observational Endpoints:  Immunogenicity  
Antibody titers against meningococcal serogroups A, C, Y, and W measured 
by [CONTACT_394283] 
(rSBA) assessed at baseline (D0, before vaccination) and 30  days (+14  days) 
after vaccination in a subset of subjects for all groups  
Safety 
â€¢ Occurrence, nature (Medical Dictionary for Regulatory Activities [MedDRA] preferred term), duration, intensity, and relationship to 
vaccination of any unsolicited systemic AEs reported in the 30  minutes 
after vaccination. 
â€¢ Occurrence, time of onset, number of days of occurrence, intensity, 
action taken, and whether the rea ction led to early termination from the 
study, of solicited (prelisted in the subjectâ€™s diary card and electronic 
case report form [CRF]) injection site reactions occurring up to 7  days 
after vaccination. 
â€¢ Occurrence, time of onset, number of days of occurr ence, intensity, 
action taken, and whether the reaction led to early termination from the study, of solicited (prelisted in the subjectâ€™s diary card and CRF) 
systemic reactions occurring up to 7  days after vaccination.  
â€¢ Occurrence, nature (MedDRA preferred term), time of onset, duration, 
intensity, action taken, relationship to vaccination (for systemic AEs only), and whether the event led to early termination from the study, of 
unsolicited AEs up to Visit  2 after vaccination.  
 
 
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 10 of 80
[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 11 of 79 â€¢ Occurrence, nature (MedDRA pr eferred term), time of onset, duration, 
seriousness criteria, relationship to vaccination, outcome, and whether 
the SAE led to early termination from the study, of SAEs throughout 
the trial. 
â€¢ Occurrence, nature (MedDRA preferred term), time of onset, duration, 
seriousness, relationship to vaccination, and outcom e for MAAE s from 
Visit [ADDRESS_494784]. MAAE s will be collected as 
unsolicited AEs up to Visit  2.  
Planned Sample Size:  A total of 3 300 subjects are planned to be enrolled:  
â€¢ Group 1: MenACYW conjugate vaccine (Lot 1):  
planned = 900 (evaluable = 810) 
â€¢ Group  1a: 400 subjects 10 to 17 years of age  
â€¢ Group 1b: 500 subjects 18 to 55 years of age 
â€¢ Group 2: MenACYW conjugate vaccine (Lot 2):  
planned = 900 (evaluable = 810) 
â€¢ Group  2a: [ADDRESS_494785] s 10 to 17 years of age  
â€¢ Group  2b: 500 subjects 18 to 55 years of age 
â€¢ Group 3: MenACYW conjugate vaccine (Lot 3):  
planned = 900 (evaluable = 810) 
â€¢ Group  3a: 400 subjects 10 to 17 years of age  
â€¢ Group  3b: 500 subjects 18 to 55 years of age 
â€¢ Group 4: MenactraÂ®: 
planned = 600 (evaluable = 540) 
â€¢ Group  4a: 300  subjects 10 to 17 years of age  
â€¢ Group  4b: 300 subjects 18 to 55 years of age 
The planned number of subjects is based on a 1 0% dropout rate allowing  
around 88% power to reject the primary hypotheses simultaneously  
assuming the independence between each of the endpoints.  
Schedule of Study Procedures : Vaccination  
All subjects will receive a single dose  of MenACYW conjugate vaccine 
from 1 of the 3  lots (Lot  1, Lot  2, or Lot  3) or MenactraÂ® on D0.  
Blood sampling  
All subjects will provide a pre- vaccination blood sample at D0 and a post -
vaccination sample at Visit  2 (30 to 44 days after the vaccination at Visit  1). 
A, C, Y, and W antigens of MenACYW conjugate vaccine (Groups  1, 2, and 
3) and MenactraÂ® (Group  4) will be measured by [CONTACT_357254], and 
by [CONTACT_357255] a subset of 100 subjects per treatment group.  
 Collection of safety data  
â€¢ All subjects will be observed for 30  minutes after vaccination, and any 
unsolicited systemic AEs occurring during that time will be  recorded as 
immediate unsolicited systemic AEs in the CRF.  
â€¢ The subject or the subjectâ€™s parent / guardian will record information in a diary card about solicited reactions from D0 to D07 after vaccination 
and unsolicited AEs from D0 to Visit  2. SAEs will be reported 
throughout the duration of the trial.  
â€¢ The subject or the subjectâ€™s parent / guardian will record information 
about any possible SAEs and MAAEs in a memory aid (MA) from 
Visit 2 until the 6 -month (+14 days) telephone call.  
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 11 of 80
[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 12 of 79  â€¢ In addition, the subject or subjectâ€™s parent / guardian will be asked to 
notify the site immediately about any potential SAEs at any time during 
the trial. 
 â€¢ Staff will contact [CONTACT_29159]â€™s parent / guardian by 
[CONTACT_72856] D08 (+2 days) to identify the occurr ence of any SAE not 
yet reported and to remind them to comple te the diary card up to Visit  2 
and to bring it back at Visit  2. 
â€¢ The completed diary card will be reviewed with the subject and/or the subjectâ€™s parent / guardian at Visit  2. 
 â€¢ Staff will contact  [CONTACT_29159]â€™s parent / guardian by 
[CONTACT_1381] 6  months (+14  days) after vaccination to review the MA 
and ident ify the occurrence of any MAAE s, as well as SAEs that may 
have not been reported. 
Duration of Participation in the Trial: The d uration of each subjectâ€™s participation in the trial will be approximately 
180 to 194 days.  
There will be a safety follow -up telephone call at 6 months (+14  days) after 
vaccination for subjects in all groups.  
Investigational Product:  MenACYW conjugate vac cine: Meningococcal Polysaccharide 
(Serogroups  A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine  ([COMPANY_011] 
Pasteur Inc., Swiftwater, PA, [LOCATION_003])  
 Form: Liquid Solution  
 Composition: Each 0.5  milliliters ( mL) dose of MenACYW conjugate vaccine  is 
formulated in sodium acetate buffered saline solution to contain the following ingredients:  
Meningococcal capsular polysaccharides:  
Serogroup A .................................................................. 10 micrograms ( Âµg) 
Serogroup C  .........................................................................................  10 Âµg 
Serogroup Y .........................................................................................  10 Âµg 
Serogroup W  ........................................................................................  10 Âµg 
Tetanus toxoid protein carrier  ......................................  approximately 65  Âµg 
 Route: Intramuscular (IM)  
 Batch Number:  3 Lots ( UD18368, UD18364, UD18365 ) 
Control Product:  MenactraÂ®: Meningococcal (Groups A, C, Y and W -135) Polysaccharide 
Diphtheria Toxoid Conjugate Vaccine ([COMPANY_011] Pasteur Inc., Swiftwater, PA, 
[LOCATION_003])  
 Form: Solution for injection  
 Composition: Each 0.5  mL dose of vaccine is formulated in sodium phosphate buffered 
isotonic sodium chloride solution to contain the following  ingredients : 
Serogroup A ............................................................................................  4 Âµg 
Serogroup C .............................................................................................  4 Âµg 
Serogroup Y ............................................................................................  4 Âµg 
Serogroup W -135 ....................................................................................  4 Âµg 
Diphtheria  toxoid protein carrier  ................................... approximately 48  Âµg 
 Route: IM 
 Batch Number:  U5462AB  (provided by [CONTACT_1034])  
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 12 of 80
[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 13 of 79 Inclusion Criteria:  An individual must fulfill all of the following criteria in order to be eligible 
for trial enrollment:  
1) Aged 10 to 55  years on the  day of inclusion  
2) Informed consent form has been signed and dated by [CONTACT_423] (aged 
18 to 55  years) or a ssent form has been signed and dated by [CONTACT_394284](s) 
or guardian  (for subjects aged 10 to <  18 years)  
3) Subject (â‰¥  18 years) or subject (10 to < 18 years) and parent / guardian 
are able to attend all scheduled visits and to comply with all trial 
procedures  
Exclusion Criteria:  An individual fulfilling any of the following criteria is to be excluded from 
trial enrollment:  
1) Subject is pregnant, or lactating, or of childbearing potential (to be 
considered of non -childbearing potential, a female must be pre-
menarche or post -menopausal for at least [ADDRESS_494786] 4 weeks after vaccination)  
2) Participation in the [ADDRESS_494787] igating a vaccine, drug, medical device, or medical procedure  
3) Receipt of any vaccine in the 4 weeks  (28 days)  preceding the trial 
vaccination or planned receipt of any vaccine prior to Visit  [ADDRESS_494788] 2 weeks before or after the study investigational vaccines. This exception includes monovalent pandemic influenza vaccines and multivalent influenza 
vaccines  
4) Previous vaccination against meningococcal disease with either the trial vaccine or another vaccine (i.e., mono - or polyvalent, polysaccharide, or 
conjugate meningococcal vaccine containing serogroups A, C, Y, or W; or meningococcal B vaccine)  
5) Receipt of immune globulins, blood or blood -derived products in the 
past 3 months  
6) Known or suspected congen ital or acquired immunodeficiency; or 
receipt of immunosuppressive therapy, such as anti -cancer 
chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for 
more than [ADDRESS_494789] 3 months)  
7) History of meningococcal infection, confirmed either clinically, serologically, or microbiologically  
8) At high risk for meningococcal infection during the trial (specifically, but not limited to, subjects with persistent complement deficiency, with 
anatomic or functional asplenia, or subjects traveling to countries with high endemic or epi[INVESTIGATOR_167467])  
9) Known systemic hypersensitivity to any of the vaccine components, or history of a life- threatening reaction to the vaccines used in the trial or 
to a vaccine containing any of the same substances  
10) Verbal report of thrombocytopenia, as reported by [CONTACT_29159]â€™s parent / guardian, contraindicating intramuscular vaccination in the Investigatorâ€™s opi[INVESTIGATOR_394275]/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 13 of 80
[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 14 of 79 11) Bleeding d isorder, or receipt of anticoagulants in the 3 weeks preceding 
inclusion, contraindicating intramuscular vaccination in the 
Investigatorâ€™s opi[INVESTIGATOR_1649]  
12) Personal history of Guillain -Barre syndrome (GBS)  
13) Personal history of an Arthus -like reaction after vaccinati on with a 
tetanus toxoid -containing vaccine within 10 years of the proposed study 
vaccination  
14) Deprived of freedom by [CONTACT_29511], or in an 
emergency setting, or hospi[INVESTIGATOR_29476]  
15) Current alcohol abuse or drug addiction  
16) Chroni c illness that, in the opi[INVESTIGATOR_871], is at a stage 
where it might interfere with trial conduct or completion  
17) Moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination or febrile illness (temper ature 
â‰¥ 100.4Â°F). A prospective subject should not be included in the study 
until the condition has resolved or the febrile event has subsided  
18) Receipt of oral or injectable antibiotic therapy within [ADDRESS_494790] blood draw  
19) Identified as an I nvestigator or employee of the Investigator or study 
center with direct involvement in the proposed study, or identified as an 
immediate family member (i.e., parent, spouse, natural or adopted child) 
of the Investigator or employee with direct involvement in the proposed 
study 
Statistical Methods:  All immunogenicity analyses will be performed on the Per -Protocol 
Analysis Set (PPAS). Additional immunogenicity analyses will be performed for exploratory purposes on the Full Analysis Set (FAS) 
according to randomization group. All safety analyses will be performed on 
the Safety Analysis Set (SafAS).  
 Primary Objective [ADDRESS_494791] meningococcal serogroups A, C, Y, and W in 
Groups  1, 2, and 3 are equivalent.  
 Null hypothesis (H 0): GMT (Gi) / GMT (Gj) â‰¤ 1/2 or GMT (Gi) / GMT( Gj) â‰¥ 2 for 
any i â‰  j  
Alternative hypothesis (H 1): 1/2 < GMT (Gi) / GMT (Gj) < 2 for all i â‰  j 
GMT (Gi) and GMT (Gj) are the GMTs of antibodies against the meningococcal 
serogroups A, C, Y, and W for the ith and jth lots , respectively. Each of the 
antigens of A, C, Y, and W serogroups will be tested separately. If the 2 -
sided 95% confidence interval (CI) of the ratio of the GMTs is >  1/2 and <  2 
for each antigen, the non -equivalence assumption will be rejected.  
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 14 of 80
[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 15 of 79  Primary Objective 2  
Non-inferiority of MenACYW conjugate vaccine compared to MenactraÂ® in 
terms of hSBA vaccine seroresponse  
 Thirty days after the administration of MenACYW conjugate vaccine or 
MenactraÂ®, the percentages of subjects who achieve an hSBA vaccine 
seroresponse* for  meningococcal serogroups A, C, Y, and W in Groups  1, 2, 
and 3 combined are non- inferior to the corresponding percentages in 
Group  4. 
 Null hypothesis (H 0): p(G123)  - p(G4) â‰¤ -10% 
Alternative hypothesis (H 1): p(G123) - p( G4) > -10% 
where p(G123)  and p(G4)  are the percentages of subjects who achieve an hSBA 
vaccine seroresponse in Groups 1 - 3 pooled and Group  4, respectively. 
Each of the serogroups A, C, Y, and W will be tested separately. If the lower 
limit of the 2 -sided 95% CI of the difference between the 2  proportions is > 
-10%, the inferiority assumption will be rejected.  
 Secondary Objective  1 
Non-inferiority of MenACYW conjugate vaccine compared to MenactraÂ® in 
terms of hSBA vaccine seroresponse in the adult population (1 8 to 55  years 
old) 
Thirty days after the administration of MenACYW conjugate vaccine or 
MenactraÂ®, the percentages of subjects who achieve an hSBA vaccine 
seroresponse* for meningococcal serogroups A, C, Y, and W in Groups  1b, 
2b, and 3b combined are non -inferior to the corresponding percentages in 
Group  4b. 
Null hypothesis (H 0): p(G123)  - p(G4) â‰¤ -10% 
Alternative hypothesis (H 1): p(G123) - p(G4) > -10% 
where p(G123)  and p(G4)  are the percentages of subjects who achieve an hSBA 
vaccine seroresponse in Groups 1b, 2b, and  3b pooled and Group  4b, 
respectively. Each of the serogroups A, C, Y, and W wi ll be tested 
separately. If the lower limit of the 2 -sided 95% CI of the difference  
between the 2  proportions is >  -10%, the inferiority assumption will be 
rejected.  
 * hSBA vaccine seroresponse for serogroups A, C, Y, and W is defined as: 
â€¢ For a subject w ith a pre -vaccination titer <  1:8, the post -
vaccination titer must be â‰¥ 1:16.  
â€¢ For a subject with a pre- vaccination titer â‰¥  1:8, the post -
vaccination titer must be at least 4 -fold greater than the pre -
vaccination titer.  
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 15 of 80
[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 16 of 79  Secondary Objective 2  
Non-inferiority of MenACYW conjugate vaccine compared to MenactraÂ® in 
terms of hSB A vaccine seroresponse in the adolescent population (10 to 
17 years old)  
Thirty days after the administration of MenACYW conjugate vaccine or 
MenactraÂ®, the percentages of subjects who achieve an hSBA vaccine 
seroresponse* for meningococcal serogroups A, C , Y, and W in Groups  1a, 
2a, and 3a combined are non- inferior to the corresponding percentages in 
Group  4a 
Null hypothesis (H 0): p(G123) - p(G4) â‰¤ -10% 
 Alternative hypothesis (H 1): p(G123) - p(G4) > -10% 
where p(G123) and p(G4) are the percentages of subjects who achieve an hSBA 
vaccine seroresponse in Groups 1a, 2a, and 3a pooled and Group 4a, 
respectively. Each of the serogroups A, C, Y, and W  will be tested 
separately. If the lower limit of the 2 -sided 95% CI of the difference 
between the 2  proportions is >  -10%, the inferiority assumption will be 
rejected.  
 Secondary Objective 3 
Comparison of 3 MenACYW conjugate vaccine lots in terms of hSBA  
vaccine seroresponse  
The difference in percentages of subjects who achieve an hSBA vaccine 
seroresponse * 30 days after the administration of MenACYW conjugate 
vaccine for meningococcal serogroups A, C, Y, and W in Groups  1, 2, and 3 
will be calculated for  each comparison and 95% CI will be provided.  
* hSBA vaccine seroresponse for serogroups A, C, Y, and W is defined as:  
â€¢ For a subject with a pre-vaccination titer <  1:8, the post -
vaccination titer must be â‰¥  1:16.  
â€¢ For a subject with a pre-vaccination titer â‰¥ 1:8, the post -
vaccination titer must be at least 4 -fold greater than the pre -
vaccination titer.  
 Secondary Objective 4 
Comparison of MenACYW conjugate vaccine to MenactraÂ® in terms of 
hSBA GMTs  
The ratio of GMTs of meningococcal serogroups A, C, Y, and W between 
the MenACYW conjugate vaccine Groups  1- 3 pooled (Lots  1, 2, and 3 
combined) and the MenactraÂ® Group  4 30 days after the administration of 
vaccine will be calculated and 95% CI will be provided.  
 Observational Objectives  
Immunogenicity 
Descriptive statistics will be provided for the antibody titers against 
meningococcal serogroups contained in each lot of MenACYW conjugate vaccine and Menactra
Â®.  
In general, categorical variables will be summarized and presented by [CONTACT_211261], percentages, and CIs. The 95% CIs of point estimates will 
be calculated using the normal approximation for quantitative data and the 
exact binomial distribution (Clopper -Pearson method) for percentages. For 
GMTs, 95% CIs of point estimates will be calculated using norm al  
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 16 of 80
[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 17 of 79  approximation assuming they are log- normally distributed. Reverse 
cumulative distribution curve (RCDC) figures will be provided for the 
antibody titers against meningococcal serogroups.  
 In summary, descriptive analyses on A, C, Y, and W serogroups will include 
but not be limited to:  
â€¢ hSBA GMTs and 95% CI at each time point for each group  
â€¢ hSBA titer distribution and RCDC 
 â€¢ Proportion of subjects with hSBA titer â‰¥ 1:4 and â‰¥ 1:8 and 95% CI 
at D0 and D30 for each group 
â€¢ Proportion of subjects with hSBA ti ter â‰¥ 4-fold rise from pre -
vaccination to post -vaccination, and 95% CI  
â€¢ rSBA GMTs and 95% CI at each time point in a subset of 
100 subjects in each  group 
â€¢ rSBA titer distribution and RCDC 
â€¢ Proportion of subjects with rSBA titer â‰¥ 1:8 and â‰¥ 1:128 and 95% 
CI at D0 and D30 in a subset of 100 subjects in  each group  
 â€¢ Proportion of subjects with rSBA titer â‰¥  4-fold rise from pre -
vaccination to post -vaccination and 95% CI  
â€¢ Vaccine seroresponse* against meningococcal serogroups A, C, Y, 
and W measured by [CONTACT_394285] 95% CI 
* rSBA vaccine seroresponse is defined as a post- vaccination titer â‰¥  1:32 for 
subjects with pre -vaccination rSBA titer < 1:8, or a post -vaccination titer 
â‰¥ 4 times the pre -vaccination titer for subjects with pre -vaccination rSBA 
titer â‰¥ 1:8.  
 Safety 
Safety results will be described for subjects in all study groups. The main 
parameters for the safety endpoints will be described by 95% CIs (based on the Clopper -Pearson method).  
 Calculations of Sample Size  
 
 
 
  
 
 
 
 
 
 
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 17 of 80

[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 18 of 79   
 
   
   
     
     
     
     
     
 
 
 
 
 
   
   
     
     
     
     
     
 
 
 
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 18 of 80

[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page [ADDRESS_494792] 
Visit/Contact [CONTACT_4838] 1 Telephone  
Call 1 Visit 2 Telephone  
Call 2 
Trial timelines (days)  Day 0  Day 8  Day 30  Day 180  
Time windows (days)  -- +2 days  +14 days  +14 days  
Informed co nsent form/assent form (if applicable)  X    
Inclusion/exclusion criteria  X    
Collection of demographic data  X    
Urine pregnancy test (if applicable)  X    
Medical history  X    
Physical examination * X    
Review of temporary contraindications for bloo d 
sampling â€    X  
Randomization/allocation of subject number  X    
Blood sampling (BL), 10 mL â€¡ BL1  BL2  
Vaccination Â§ X    
Immediate surveillance (30 minutes ) X    
Diary card provided  X    
Telephone call   X**  Xâ€ â€  
Recording of solicited injection site  & systemic 
reactions D0 to 
D07    
Recording of unsolicited AEs  Visit [ADDRESS_494793] reviewed and collected    X  
Recording of MAAE sâ€¡â€¡    After Visit  2 to TC2  
Reporting of SAEs  To be reported throughout the study period  
Collection of reportab le concomitant medications  X  X  
Memory aid (MA) providedÂ§Â§   X  
Termination of active phase of trial    X  
Completion of 6 -month follow -up    X 
*Temperature needs to be measured and recorded in source document s. 
â€ Should a subject receive oral or inject able antibiotic therapy within [ADDRESS_494794] still be within the timeframe for blood draw (30 to 44 days after vaccination at D0).  If postponement would 
result in the sample collection falling outside of this timeframe, the blood sample should be collected without postponement,  and 
it should be documented appropriately that the sample was taken less than 3  days after stoppi[INVESTIGATOR_29479].  
â€¡Blood sample at Visit  1 will be drawn before administration of vaccine  
Â§Subjects will receive 1  dose of MenACYW conjugate vaccine  or MenactraÂ® 
**This call is made 8 to 10  days afte r the vaccination at Visit 1. If D08 (+2  days) falls on a weekend or holiday, the telephone call 
may be made on the following business day. During this telephone call, the staff will find out whether the subject experience d 
any SAE not yet reported, and will remind the subject / subjectâ€™s parent / guardian  to continue using the diary card up to Visit  2, 
to bring the diary card to the study center at Visit  2, and confirm the date and time of Visit  2. 
â€ â€ Staff will contact [CONTACT_423] / subjectâ€™s parent / guardian by [CONTACT_1381] 6  months (180 days +14  days) after vaccination at 
Visit  1 to ident ify the occurrence of any MAAE s as well as SAEs not yet reported.  
â€¡â€¡MAAE s that occur between Visit  1 and Visit  2 will be recorded as unsolicited AEs.  
Â§Â§The MA is used for the recording of SAEs and MAA Es. The site staff will make a telephone call to the subject/subjectâ€™s parent / 
guardian to obtain the information 180 days (+14  days) after the vaccination at Visit  1. Since the timeframe between Visit  1 and 
Visit  2 (inclusive) will be captured in the diary card, the MA will be used to collect SAE and MAAE  data from Visit  2 to TC2.  
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 19 of 80
[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page [ADDRESS_494795] of Abbreviations  
Âµg microgram(s)  
AE adverse event  
AR adverse reaction  
BL blood sampling  
CDM  Clinical Data Management  
CFU colony -forming unit  
CI confidence interval  
C&MQO  Clinical and Medical Quality Operations 
CRA Clinical Research Associate 
CRF electronic case report form  
CTA clinical trial agreement  
CTL Clinical Team Le ader  
D day  
EDC  electronic data capture  
eSAE  electronic Serious Adverse Event (Form)  
FAS Full Analysis Set 
FDA  Food and Drug Administration  
FVFS first visit, first subject 
FVLS first visit, last subject 
GBS  Guillain-BarrÃ© syndrome  
GCI Global Clinical Immunology 
GCP  Good Clinical Practice 
GMT  geometric mean titer  
GMTR  geometric mean titer ratio  
GPV  Global PharmacoVigilance  
hSBA serum bactericidal assay using human complement 
IATA  International Air Transport Association  
ICF informed consent form 
ICH International Conference on Harmonisation  
IEC Independent Ethics Committee  
IgG immunoglobulin G  
IM intramuscular(ly)  
IMD invasive meningococcal disease  
IND investigational new drug (application)  
IOM  Institute of Medicine  
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 20 of 80
[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page [ADDRESS_494796] level term  
MA memory aid  
MAAE  medically -attended adverse event  
MedDRA  Medical Dictionary for Regulatory Activities 
mL milliliter (s) 
NSAID  non-steroidal anti -inflammatory drug  
PPAS  Per-Protocol Analysis Set 
PS polysaccharide(s)  
PSO Product Safety Officer  
R&D  Research and Development  
RCDC reverse cumulative distribution curve  
RMO Responsible Medical Officer  
rSBA serum bactericidal assay using baby [CONTACT_394286] T eam 
TMF Trial Master F ile 
UAR  unexpected adverse reaction  
ULOQ  upper limit of quantitation  
UTN  Universal Trial Number  
WHO  World Health Organization  
 
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 21 of 80
[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 22 of 79  
1 Introduction 
1.1 Background 
This trial will evaluate the immune lot consistency  of Meningococcal Polysaccharide (Serog roups 
A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine (hereafter referred to as MenACYW 
conjugate vaccine), evaluate the immune non -inferiority versus MenactraÂ®, and describe the 
safety and additional immunogenicity of study vaccines in adolescents and adults  10 to 55 years 
of age. 
Invasive meningococcal disease (IMD) is a serious illness caused by [CONTACT_357260] (N. meningitidis) , a Gram -negative diplococcus found exclusively in humans. 
Symptoms may include intense headache, fever, n ausea, vomiting, photophobia, stiff neck, lethargy, 
myalgia, and a characteristic petechial rash  (1). At least [ADDRESS_494797] 
been classified based on the immunochemistry of the capsular polysaccharides (PS). Some strains 
are more likely than others to cause infection (1) (2) (3). Worldwide, most cases of 
meningococcal disease are caused by [CONTACT_167508] A, B, C, X, Y, and W  (2) (3) (4). Serogroup B is 
responsible for endemic disease and some outbreaks, while serogroup C is responsible for large outbreaks  (5). Serogroup A is the main cause of epi[INVESTIGATOR_394276], and is especially 
dominant in Africa and Asia. Serogroup W has been seen in Africa, as well as in the [LOCATION_008] in residents who participated in the Hajj pi[INVESTIGATOR_167470]  (4) 
(6) (7) and more recently in Chile  (8), Turkey (9) (10), China  (11) (12) , Argentina  (13), and Brazil 
(14) (15)  and in other parts of the world. Serogroup X causes substantial meningococcal disease 
in parts of Africa but rarely causes disease in other parts of the world (2) (16). Serogroup Y has 
not been associated with outbreaks, but its frequency as a cause of sporadic cases has gradually increased in the US and more recently in Canada and Europe  (17) (18) ( 19). This serogroup is 
commonly associated with meningococcal pneumonia, partic ularly in older adults >  65 years of 
age (20). Outbreaks of serogroup B meningococcal di sease have also been reported on college 
campuses in the US during the last five- year period: a prolonged outbreak of serogroup B on a 
university campus in Ohio from 2008- 2010 and 2 universities in New Jersey and [LOCATION_004] in 
2013 (21) ( 22). 
The epi[INVESTIGATOR_14849] N. meningitidis  can be described as complex, unpredictable, geographically 
variable, and changing over time. Meningococcal disease occurs worldwide in both endemic and epi[INVESTIGATOR_357238]. In Europe, the incidence rate of IMD has remained stable over the last [ADDRESS_494798] incidence rate in Europe is 
caused by [CONTACT_167509] B, followed by C  (23). The highe st proportion of meningococcal cases was 
due to serogroup B in the population under [ADDRESS_494799] in th e population aged 65 years and above. 
Surveillance data from England and Wales showed an increase in endemic meningococcal serogroup W disease across all age groups, accounting for 15% of all IMD cases in 2013-2014 compared with an average of 1% to 2% of a ll IMD cases in earlier years (24). A gradual increase 
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 22 of 80
[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 23 of 79 in serogroup Y IMD has also been recently reported in Sweden during 2005-2012 (25) (26). 
Nearly 50% of all IMD was caused by [CONTACT_167509] Y in 2012 (25) . Similarly, an increase in the 
proportion of IMD caused by [CONTACT_167509] Y has been observed in other Scandinavian countries, 
accounting for 31% in Norway in 2009-2010 and 38% in Finland in 2010 (27).  
In the US, the incidence rate of IMD w as 0.14 per 100,000 in all ages; 0.83 per 100,000 in infants 
less than 1 year; 0.62 per 100,000 in toddlers 1 year of age; 0.27 per 100,000 in children 2 to 4 years of age; and 0.02 per 100,000 in children 5 to 17 years of age in 2013. The age specific 
incidence rate per 100,000 was 0.08 in adults 50 to 64 years of age, 0.03 in adults 65 to 74 years of age, 0.14 in adults 75 to 84 years of age, and 0.43 in adults 85 years of age and older in 2013 (28).  
The goal for MenACYW conjugate vaccine is to provide broad protection against IMD caused by [CONTACT_167508] A, C, Y, and W in all target age groups.  
1.[ADDRESS_494800]  
1.2.1 Non-clinical Safety  
 
 
 
 
 
1.2.2 Clinical 
The MenACYW conjugate vaccine formulation was finalized based on data provided by 2 studies: MET28, a Phase I study in infants, toddlers, and adults 18 to 55 years of age; and 
MET32, a Phase I/II study in toddlers. 
The formulation has been evaluated in over 650 subjects (infants, toddlers, and adults > 55 years 
of age) in MET39 and MET44. Both Phase II studies are discussed below.  In addition, the vaccine 
has been evaluated in another Phase II study in 10 to 17 year olds in the US (MET50). The MET50 study evaluated the safety and immune response of the MenACYW conjugate vaccine when administered alone or along with Tdap and HPV vaccine administered concurrently as compared to a licensed vaccine (MENVEO
Â®). A total of 895 subjects received the Me nACYW 
conjugate vaccine in this study. The follow up of this study has been completed; however, analysis is still ongoing. No safety concerns or signals  were identified in this study.  
The MenACYW conjugate vaccine was found to be well tolerated and no unanticipated or new significant safety concerns have been identified in the clinical trials completed to date.  
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 23 of 80

[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 24 of 79 [IP_ADDRESS] Study MET39 (Phase II)  
MET39 was a Phase II, randomized, open- label, multi-center study conducted in the US for which 
580 healthy subjects from 2 to 15 months of age were enrolled. This study evaluated the optimal 
vaccination schedule in the infant/toddler population. Subjects in Group 1 through Group 4 received 1, 2, or 3 primary doses plus an additional dose of the MenACYW conjugate vaccine in the second year of life, concomitantly with routine pediatric vaccines at several different vaccination schedules. Subjects in Group 5 received 1 dose of the MenACYW conjugate vaccine concomitantly with routine pediatric vaccines. The routine pediatric vaccines given concomitantly with MenACYW conjugate vaccine at various schedules included Prevnar
Â® or Prevnar 13Â®, 
PentacelÂ®, ROTARIXÂ® or RotaTeqÂ®, hepatitis B vaccine, M-M-RÂ® II, and VARIVA XÂ®. 
Immunogenicity 
After the primary series consisting of 1, 2, or 3 doses of MenACYW  conjugate vaccine, protective 
serum bactericidal assay using human complement (hSBA) threshold titers of â‰¥ 1:8 were attained 
by > 88% of subjects for serogroup C and by 62% to 74% for serogroup A. For serogroups Y and W, â‰¥ 90% achieved the threshold titer  after 3  doses, 75% to 84% after 2 doses, but only 25% after 
a single dose administered at 6  months of age.  
After an additional dose of MenACYW conjugate vaccine in the second year of life (12 or 15 months), between 91% and 100% of the subjects achieved t he protective threshold regardless 
of the number of doses they received in the first year of life.  
Safety 
MenACYW conjugate vaccine was well tolerated in infants and toddlers regardless of the 
immunization schedule and the number of doses administered. Saf ety results were comparable to 
those seen in control group subjects regardless of the immunization schedule and the number of doses administered. The safety profile of the licensed vaccines given concomitantly with MenACYW conjugate vaccine was similar to that of the licensed vaccines given concomitantly 
without MenACYW conjugate vaccine. 
No deaths occurred within 30 days. There were 2 subjects in Group 4 who died during the study, 
1 as a result of hypoxic ischemic encephalopathy which started 96 days after  the 6-month 
vaccination and 1 as a result of non- accidental head trauma 36  days after the 12 -month 
vaccination. These events were considered by [CONTACT_357261]. There were 2  other subjects who discontinued the study due to a serious adverse event (SAE) and 
the receipt of intravenous immunoglobuli n treatment: [ADDRESS_494801] in Group 2 with Kawasaki 
disease, 106  days after the 6 -month vaccination; and [ADDRESS_494802] in Group 4 was discontinued due to a non- serious adverse event (AE ) (viral 
rash 1  day after the 6-month vaccinations). None of these AEs leading to discontinuation were 
considered by [CONTACT_167512]. There were no related SAEs during this study. 
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 24 of 80
[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 25 of 79 [IP_ADDRESS] Study MET44 (Phase II)  
MET44 was a Phase II, randomized, open-label (the laboratory technicians were blinded to group 
assignment), multi-center study conducted in the US. This study evaluated the immunogenicity and safety profiles of a single dose of MenACYW conjugate vaccine when administered to adults 56 years of age and older. A total of 301 subjects aged 56 years and older on the day of enrollment were randomized to receive a single dose of MenACYW conjugate vaccine or Menomune
Â® - A/C/Y/W -135; each group was stratified according to age into 2 subsets (subjects 
56 to 64 years of age and subjects â‰¥ 65 years of age).  
Immunogenicity 
The proportions of subjects with hSBA titers â‰¥ 1:8 obtained after MenACYW conjugate vaccine 
administration (Group 1) for serogroups A and C were comparable to, or for serogroups Y and W 
higher than, those obtained after MenomuneÂ® - A/C/Y/W -135 administration (Group 2): 93.8% in 
Group 1 and 85.1% in Group 2 for serogroup A; 74.9% in Group 1 and 62.8% in Group 2 for serog roup C; 80.5% in Group 1 and 59.6% in Group 2 for serogroup Y; 79.5% in Group 1 and 
60.6% in Group 2 for serogroup W. 
Within each group of those who received MenACYW conjugate vaccine or Menomune
Â® - 
A/C/Y/W -135, the proportions of subjects with hSBA titers  â‰¥ 1:8 were comparable between the 
subset of subjects 56 to 64 years of age and the subset â‰¥ 65 years of age, for all serogroups. The hSBA geometric mean titers (GMTs) after MenACYW conjugate vaccine administration for 
serogroups A and W were comparable to, or for serogroups C and Y higher than, those after Menomune
Â® - A/C/Y/W -135 administration. Responses with SBA using baby [CONTACT_357262] 
(rSBA) in general demonstrated the same trend as with hSBA.  
Safety 
Vaccination with MenACYW conjugate vaccine or MenomuneÂ® - A/C/Y/W -135 among adults 
56 years of age and older was found to be well tolerated, with no safety concerns identified. There 
were no immediate unsolicited AEs/reactions reported in either group. There were no deaths, SAEs or AEs that led to study discontinuation reported during the study. 
The safety profile of the vaccine when compared by [CONTACT_357263], with no clinical impact in the differences observed. In general, no increase in reactogenicity was observed in the older vaccine recipi[INVESTIGATOR_394277]. 
1.[ADDRESS_494803] benefit from receiving the MenACYW conjugate vaccine. However, based on the data generated from previous studies, the immunogenicity profile of the MenACYW conjugate vaccine in different age groups shows that the majority of subjects developed seroprotective levels of antibodies after vaccination. The safety evaluation indicates 
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 25 of 80
[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page [ADDRESS_494804] been detected to date. In all, the data 
support further evaluation of the MenACYW conjugate vaccine in humans. 
Subjects who receive MenactraÂ® will likely be protected against meningococcal disease caused by 
N. meningitidis  serogroups A, C, Y, and W. 
As with any vaccine, MenACYW conjugate vaccine and MenactraÂ® may not protect 100% of 
individuals against the diseases they are designed to prevent.  
1.3.2 Potential Risks to Subjects  
Like other vaccines, vaccination with MenACYW conjugate vaccine or MenactraÂ® may cause 
injection site reactions such as pain, swelling, and erythema, or certain systemic events such as 
fever, headache, malaise, or myalgia.  
Other common reactions after MenactraÂ® in the studied age group include injection site 
induration, fatigue, arthralgia, appetite lost, and diarrhea . 
There may be a rare possibility of an allergic reaction which cou ld be severe. Prior to any vaccine 
injection, all known precautions should be taken to prevent hypersensitivity reactions. This 
includes a review of the subjectâ€™s prior vaccination history with respect to possible hypersensitivity to the vaccine or similar  vaccines. Epi[INVESTIGATOR_156705] (1:1000) and other 
appropriate agents used for the control of immediate allergic reactions must be available to treat unexpected reactions (e.g., anaphylaxis).  
There may be other risks for MenACYW conjugate vaccine which ar e not yet known. 
The following additional adverse events have been very rarely reported during post-approval use of Menactra
Â®: Guillain -BarrÃ© syndrome (GBS), transverse myelitis, acute disseminated 
encephalomyelitis, vasovagal syncope, facial palsy, dizziness, paraesthesia, convulsion, and hypersensitivity reactions such as anaphylactic / anaphylactoid reaction, wheezing, difficulty breathing, upper airway swelling, urticaria, erythema, pruritus, and hypotension. Because these events were reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or to establish a causal relationship to Menactra
Â® exposure. 
GBS has been reported  mostly  in persons aged 11 to 19 years who had symptom onset within 
6 weeks of  administration of MenactraÂ® (29). A retrospective cohort study carried out in the US 
using healthcare claims data found no evidence of increased GBS risk following MenactraÂ® 
vaccination. The study was able to exclude all but relatively small incremental risks  (30). 
A review by [CONTACT_120845] (IOM) found inadequate evidence to accept or reject a causal relationship between tetanus toxoid-containing vaccines and GBS  (31). The IOM found 
evidence for a causal relation between tetanus toxoid -containing vaccines and brachial neuritis  
(32). Arthus reactions are rarely reported after vaccination and can occur after tetanus toxoid-
containing vaccines (33).  
No occurrences of GBS, brachial neuritis, or Arthus reaction have been reported with the use of MenACYW conjugate vaccine in the completed clinical trials.  
 
 
 
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 26 of 80

6DQRIL3DVWHXU 0(7
Â±0HQ$&<:&RQMXJDWH9DFFLQH
&RQILGHQWLDO3URSULHWDU\,QIRUPDWLRQ
3DJHRI


,PSRUWDQWO\QRVLPLODUFDVHVKDYHEHHQUHSRUWHGIROORZLQJWKH
DGPLQLVWUDWLRQRI0HQ$&<:FRQMXJD WHYDFFLQHLQDQ\RWKHUWULDOV 
7KHULVNRIYDVRYDJDOV\QFRSHH[LVWVDIWHUDQ\YDFFLQDWLRQLQW KHDGROHVFHQWDJHJURXS$IHZ
FDVHVRILPPHGLDWHYDVRYDJDOOLNHUHVSRQVHRUV\QFRSHKDYHEHHQ REVHUYHGLQDGROHVFHQWVXEMHFWV
ZKRKDGUHFHLYHG0HQ$&<:FRQMXJDWHYDFFLQH6\QFRSHKDVEHHQUH SRUWHGIROORZLQJ
YDFFLQDWLRQZLWK0HQDFWUDÂŠ3URFHGXUHVVKRXOGEHLQSODFHWR SUHYHQWIDOOLQJLQMXU\DQGP DQDJH
V\QFRSDOUHDFWLRQV
7KHSRWHQWLDOULVNVDVVRFLDWHGZLWKEORRGGUDZLQJLQFOXGHORFDO SDLQEUXLVLQJDQGUDUHO\
IDLQWLQJ
7KHSRWHQWLDOULVNOLVWHGKHUHD UHQRWH[KDXVWLYH5HIHUWRWKH SDFNDJHLQVHUWRIWKHPDUNHWHG
YDFFLQHDQGWKH,QYHVWLJDWRUÂ¶V%URFKXUH IRUWKHLQYHVWLJDWLRQDOYDFFLQH IRUDGGLWLRQDO
LQIRUPDWLRQUHJDUGLQJWKHSRWHQWLDOULVNV
5DWLRQDOHIRUWKH7ULDO
7KH0HQ$&<:FRQMXJDWHYDFFLQHLV GHVLJQHGIRUWKHLPPXQL]DWLRQ RILQGLYLGXDOVRIDOODJHV
LQIDQWVZHHNVRIDJHDQGROGH UWKURXJKDQGLQFOXGLQJROGHUD GXOWV!\HDUVRIDJHDJDLQVW
,0'7KHSXUSRVHRIWKHYDFFLQHLVWRSURYLGHEURDGFRYHUDJHDJ DLQVWFLUFXODWLQJPHQLQJRFRFFDO
VWUDLQVIURPVHURJURXSV$&<D QG:7KH0HQ$&<:FRQMXJDWHY DFFLQHLVSUHSDUHGXVLQJ
&RQMXJDWLRQRI36DQWLJHQVW RDSURWHLQFDUULHUFDQLQGXFH
7FHOOGHSHQGHQWLPPXQHUHVSRQVHV ZKLFKDUHDQWLFLSDWHGWRJLY HULVHWRKLJKHUDQWLERG\WLWHUV
ORQJHUGXUDWLRQRIWKHLPPXQHU HVSRQVHDQGHQKDQFHGLPPXQRORJL FPHPRU\WKDWDOORZVIRUD
ERRVWHUUHVSRQVH$PRQJWKHNH\DGY DQWDJHVH[SHFWHGRIWKHWHWD QXVFDUULHULVLPSURYHG
LPPXQRJHQLFLW\LQLQIDQWVDQGROGH UDGXOWV3UHF OLQLFDOVWXGLH VXVLQJDPRXVHPRGHODQG
LQYHVWLJDWLQJGLIIHUHQWFDUULHUV VKRZHGVLJQLILFDQWOHYHOVRI 36VSHFLILFWRWDOLPPXQRJOREXOLQ*
,J*DQGEDFWHULFLGDOUHVSRQVHVLQUHVSRQVHWRWKHIRUPXODWLRQ VZLWKWHWDQXVWR[RLGDVDFDUULHU
(DUO\3KDVH,,,WULDOVLQFOXGLQJW KRVHZLWKWKHILQDOIRUPXODW LRQ0(7DQG0(7VKRZHGWKH
SRWHQWLDORIWKHFDQGLGDWHY DFFLQHDVDYHU\JRRGLPPXQRJHQLQ DOODJHJURXSVLQFOXGLQJ\RXQJ
LQIDQWVDQGROGHUDGXOWV7KH0HQ$&<:FRQMXJDWHYDFFLQHZDVIRX QGWREHLPPXQRJHQLFDQG
ZHOOWROHUDWHGLWGLGQRWUDLVH DQ\VDIHW\FRQFHUQVLQWKHDER YHWULDOVXVLQJWKHILQDOIRUPXODWLRQRU
LQWKHHDUOLHUWULDOV
7KHSXUSRVHRI0(7LVWRGHPRQV WUDWHWKHLPPXQHORWFRQVLVWHQ F\RIWKHDQWLERG\UHVSRQVHVWR
PHQLQJRFRFFDOVHURJURXSV$&< DQG:IROORZLQJWKHDGPLQLVWU DWLRQRIDVLQJOHGRVHRI
0HQ$&<:FRQMXJDWHYDFFLQH$GGLWLRQDOO\0(7KDVWKHSXUSRVH RIGHPRQVWUDWLQJWKHQRQ
LQIHULRULW\RIWKHDQWLERG\UHVSRQVHVWRPHQLQJRFRFFDOVHURJURX SV$&<DQG:IROORZLQJWKH
DGPLQLVWUDWLRQRIDVLQJOHGRVHRI 0HQ$&<:FRQMXJDWHYDFFLQHFR PSDUHGWRWKRVHREVHUYHG
IROORZLQJWKHDGPLQLVWUDWLRQRI DVLQJOHGRVHRI0HQDFWUDÂŠ*HQHUDWLRQRILPPXQHORWFRQVLVWHQF\
GDWDDQGLPPXQHQRQLQIHULRULW\YHUVXVDOLFHQVHGYDFFLQHLVDQ LPSRUWDQWUHJXODWRU\UHTXLUHPHQW
IRUUHJLVWUDWLRQRI WKLVYDFFLQH6DQRIL3DVWHXU 

&RQILGHQWLDO3URSULHWDU\,QIRUPDWLRQ
0(7
Â±0HQ$&<:&RQMXJDWH9DFFLQH 3URWRFRO9HUVLRQ
3DJHRICCI
[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 28 of 79 2 Trial Objectives  
2.1 Primary Objectives  
1) To demonstrate the immune lot consistency of the antibody responses t o meningococcal 
serogroups A, C, Y, and W following the administration of a single dose of MenACYW 
conjugate vaccine with respect to serum bactericidal assay using human complement (hSBA) geometric mean titers (GMTs)  
2) To demonstrate the non- inferiority of t he antibody responses to meningococcal serogroups A, 
C, Y, and W following the administration of a single dose of MenACYW conjugate vaccine (pooled Lots 1 to 3) compared to those observed following the administration of a single dose of Menactra
Â® 
The endpoints for the primary objectives are presented in Section [IP_ADDRESS].  
2.2 Secondary Objective s 
1) To demonstrate the non-inferiority of the antibody responses to meningococcal serogroups A, C, Y, and W following the administration of a single dose of MenACYW conjugate vaccine (pooled Lots 1 to 3) compared to those observed following the administration of a single dose of Menactra
Â® in the adult population (18 to 55 years old) 
2) To demonstrate the non- inferio rity of the antibody responses to meningococcal serogroups A, 
C, Y, and W following the administration of a single dose of MenACYW conjugate vaccine (pooled Lots 1 to 3) compared to those observed following the administration of a single dose of Menactra
Â® in the adolescent population (10 to 17 years old) 
3) To compare the hSBA vaccine seroresponses of meningococcal serogroups A, C, Y, and W 
for each of 3 lots of MenACYW conjugate vaccine 30 days (+14 days) after vaccination  
4) To compare the hSBA antibody GMTs of meningococcal serogroups A, C, Y, and W following the administration of MenACYW conjugate vaccine to those observed following the administration of Menactra
Â® 
The endpoints for the secondary objectives are presented in  Section [IP_ADDRESS]. 
2.3 Observational Objectives 
Immunogenicity  
To describe the antibody responses to the meningococcal serogroups A, C, Y, and W before and 30 days (+14  days) after vaccination with MenACYW conjugate vaccine or Menactra
Â® 
Safety 
To describe the safety profile of MenACYW conjugate vaccine and that of the licensed 
MenactraÂ® 
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 28 of 80
6DQRIL3DVWHXU 0(7
Â±0HQ$&<:&RQMXJDWH9DFFLQH
&RQILGHQWLDO3URSULHWDU\,QIRUPDWLRQ
3DJHRI7KHHQGSRLQWVIRUWKHREVHUYDWLRQDOREMHFWLYHVDUHSUHVHQWHGLQ 6HFWLRQ DQG
6HFWLRQ IRULPPXQRJHQLFLW\DQGVDIHW\UHVSHFWLYHO\
,QYHVWLJDWRUVDQG7ULDO2UJDQL]DWLRQ
7KLVWULDOZLOOEHFRQGXFWHGLQD SSUR[LPDWHO\ FHQWHUVLQWKH 8QLWHG6WDWHV7KH3ULQFLSDO
,QYHVWLJDWRUVDQGDQ\VXELQYHVWLJ DWRUVDWWKHLQGLYLGXDOVLWHV ZLOOEHFRRUGLQDWHGE\RQH
&RRUGLQDWLQJ,QYHVWLJDWRU'HWDL OVRIWKHWULDOFHQWHUVWKH,Q YHVWLJDWRUVDWHDFKFHQWHUDQGWKH
&RRUGLQDWLQJ,QYHVWLJDWRUVDUH SURYLGHGLQWKHÂ³/LVWRI,QYHV WLJDWRUVDQG&HQWHUV,QYROYHGLQWKH
7ULDOÂ´GRFXPHQW
$QLQWHUQDO6DIHW\0DQDJHPHQW7 HDP607ZLOOSHUIRUPDEOLQGHG VDIHW\DQDO\VLVRQVDIHW\
GDWDDIWHUYDFFLQDWLRQ
7KH6SRQVRUÂ¶V5HVSRQVLEOH0HGLFDO 2IILFHU502WKHSHUVRQDXW KRUL]HGWRVLJQWKLVSURWRFRO
DQGDQ\DPHQGPHQWVRQEHKDOIRIWKH6SRQVRULV  

,QGHSHQGHQW(WKLFV&RPPLWWHH,QVWLWXWLRQDO5HYLHZ%RDUG
%HIRUHWKHLQYHVWLJDWLRQDOSU RGXFWFDQEHVKLSSHGWRWKHLQYHVW LJDWLRQDOVLWHDQGEHIRUHWKH
LQFOXVLRQRIWKHILUVWVXEMHFWW KLVSURWRFROWKHLQIRUPHGFRQ VHQWIRUPV,&)DVVHQWIRUP
VXEMHFWUHFUXLWPHQWSURFHGXUHV DQGDQ\RWKHUZULWWHQLQIRUPDWL RQWREHSURYLGHG WRVXEMHFWVPXVW
EHDSSURYHGE\DQGRUUHFHLYHID YRUDEOHRSLQLRQIURPWKHDS SURSULDWH,QGHSHQGHQW(WKLFV
&RPPLWWHH,(&RU,QVWLWXWLR QDO5HYLHZ%RDUG,5%
,QDFFRUGDQFHZLWK*RRG&OLQLFDO3UDFWLFH*&3DQGORFDOUHJXO DWLRQVHDFK,QYHV WLJDWRUDQGRU
WKH6SRQVRUDUHUHVSRQVLEOHIRU REWDLQLQJWKLVDS SURYDODQGR UIDYRUDEOHRSLQLRQEHIRUHWKHVWDUW
RIWKHWULDO,IWKHSURWRFROL VVXEVHTXHQWO\DPHQGHGDSSURYDO PXVWEHUHREWDLQHGIRUHDFK
VXEVWDQWLDODPHQGPHQW&RSLHVRI WKHVHDSSURYDOVDORQJZLWKLQ IRUPDWLRQRQWKHW\SHYHUVLRQ
QXPEHUDQGGDWHRIGRFXPHQWDQGWKHGDWHRIDSSURYDOPXVWEH IRUZDUGHGE\WKH,QYHVWLJDWRUWR
WKH6SRQVRUWRJHWKHUZLWKWKHF RPSRVLWLRQRIWKH,(&,5%WKH QDPHVDQGTXDOLILFDWLRQVRIWKH
PHPEHUVDWWHQGLQJDQGYRWLQJDWWKHPHHWLQJV
7KH,QYHVWLJDWRURU6SRQVRUZ LOOVXEPLWZULWWHQVX[COMPANY_003]ULHVRIWK HVWDWXVRIWKHWULDOWRWKH,(&
,5%DQQXDOO\RUPRUHIUHTXHQWO\LIUHTXHVWHG$OO6$(VRFFXUUL QJGXULQJWKHWULDOWKDWDUHUHODWHG
WRYDFFLQDWLRQZLOOEHUHSRUWHGE\ WKH,QYHVWLJDWRUWRWKH,(& ,5%DFFRUGLQJWRWKH,(&,5%
SROLF\6DQRIL3DVWHXU 

&RQILGHQWLDO3URSULHWDU\,QIRUPDWLRQ
0(7
Â±0HQ$&<:&RQMXJDWH9DFFLQH 3URWRFRO9HUVLRQ
3DJHRIPII PI[INVESTIGATOR_394274]43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 30 of 79 5 Investigational P lan 
5.1 Description of the Overall Trial Design and Plan  
5.1.1 Trial Design  
This is a Phase III, modified double-blind, randomized, parallel-group, active-controlled, multi-
center study to evaluate immune lot consistency of MenACYW conjugate vaccine, evaluate the immune non- inferiority versus Menactra
Â®, and describe the safety and additional immunogenicity 
of these study vaccines in adolescents and adults aged 10 to 55 years in the United  States.  
Healthy, meningococcal- vaccine naÃ¯ve adolescents and adults will be ran domized in a 
3:3:3:2 ratio to the following groups: 
â€¢ Group 1: MenACYW conjugate vaccine (Lot 1) 
â€¢ Group 1a: 400 subjects 10 to 17 years of age 
â€¢ Group 1b: 500 subjects 1 8 to 55 years of age 
â€¢ Group 2: MenACYW conjugate vaccine (Lot 2) 
â€¢ Group 2a: 400 subjects 10 to 17 years of age 
â€¢ Group 2b: 500 subjects 18 to 55 years of age 
â€¢ Group 3: MenACYW conjugate vaccine (Lot 3) 
â€¢ Group 3a: 400 subjects 10 to 17 years of age 
â€¢ Group 3b: 500 subjects 18 to 55 years of age 
â€¢ Group 4: MenactraÂ® 
â€¢ Group 4a: 300 subjects 10 to 17 years of age 
â€¢ Group 4b: 300 subjects 18 to 55 years of age 
All subjects will provide blood samples for immunogenicity assessment at baseline (pre-vaccination) and at [ADDRESS_494805]-vaccination.  
Solicited AE information will be collected for 7 days after vaccination, unsolicited AE 
information will be collected from Visit 1 (Day [D] 0) to Visit 2 (D30 [+14 days]), and SAE  
information will be collected from D0 through D180 (+14 days) after vaccination.  Medically -attended adverse events (MAAE s) will be collected th roughout the study from Visit 1 
to Visit 2 (as part of the collection of unsolicited  AE information) and from Visit 2 through D180 
(+14 days) (as MAAEs).  
5.1.2 Justification of the Trial Design  
The purpose of MET43 is to demonstrate the immune lot consistency of the antibody responses to 
meningococcal serogroups A, C, Y, and W following the administration of a single dose of MenACYW conjugate vaccine. Additionally, MET43 has the purpose of demonstrating the non-inferiority of the antibody responses to meningococcal serogroups A, C, Y, and W following the administration of a single dose of MenACYW conjugate vaccine compared to those observed following the administration of a single dose of Menactra
Â®.  
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 30 of 80
[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 31 of 79 This study will be the only study to generate immune lot consistency data in the US and would be 
an additional study (to MET56) to generate immune non- inferiority data v ersus MenactraÂ® in age 
groups [ADDRESS_494806] and the Investigator remain 
unaware of the treatment assignments throughout the trial. An un- blinded vaccine administrator 
will administer the appropria te vaccine but will not be involved in safety data collection. The 
Sponsor and laboratory personnel performing the serology testing will also remain blinded to 
treatment assignments throughout the trial until database lock.  
5.1.3 Trial Plan  
A schedule of assessm ents and study vaccinations is provided in the  Table of Study Procedures . 
Vaccination 
All subjects will receive a single dose of MenACYW conjugate vaccine (from 1 of the 3 lots 
[Lot 1, Lot 2, or Lot 3]) or MenactraÂ® on D0. 
Blood sampling All subjects will provide a pre -vaccination blood sample at D0 and a post- vaccination sample at 
Visit 2 (30 to 44 days after the vaccination at Visit  1). 
A, C, Y, and W antigens of MenACYW conjugate vaccine (Groups 1, 2, and 3) and Menactra
Â® 
(Group 4) will be measured by [CONTACT_357254], and by [CONTACT_357255] a subset of 100 subjects 
per treatment group. 
Collection of safety data  
â€¢ All subjects will be observed for 30 minutes after vaccination, and any unsolicited systemic 
AEs occurring during that time will be recorded as imm ediate unsolicited systemic AEs in the 
electronic case report form ( CRF ). 
â€¢ The subject or the subjectâ€™s parent / guardian will record information in a diary card about 
solicited reactions from D0 to D07 after vaccination and unsolicited AEs from D0 to Visit 2. SAEs will be reported throughout the duration of the trial. 
â€¢ The subject or the subjectâ€™s parent / guardian will record information ab out any possible SAEs 
and MAAE s in a memory aid (MA) from Visit 2 until the 6 month (+14 days) telephone call.  
â€¢ In addition, the subject or subjectâ€™s parent / guardian will be asked to notify the site 
immediately about any potential SAEs at any time during the trial. 
â€¢ Staff will contact [CONTACT_29159]â€™s parent / guardian by [CONTACT_72856] D08 (+2 days) 
to identify the occurrence of any SAE not yet reported and to remind them to comple te the 
diary card up to Visit 2 and to bring it back at Visit 2. 
â€¢ The completed diary card will be reviewed with the subject and/or the subjectâ€™s parent / 
guardian at Visit 2. 
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 31 of 80
[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 32 of 79 â€¢ Staff will contact [CONTACT_29159]â€™s parent / guardian by [CONTACT_1381] 6 months 
(+14 days) after vaccination to review the MA and identify the occurrence of any MAAEs, as 
well as SAEs that may have not been reported.  
5.1.4 Visit Procedures 
Medical procedures (examinations, injections, etc.) must be conducted by [CONTACT_394287]/credentials.  At Visit 1 
(D0), visit procedures will be performed in the order listed below.  
Visit 1 (D0): Inclusion, Randomization, Blood Sample, and Vaccination
 
1) Subjects aged 10 to <  18 years : Give the subject and the subjectâ€™s parent / guardian 
information about the trial, answer any questions, obtain signed assent from subjects and the written informed consent from the subjectâ€™s parent /guardian, and give him / her  a signed 
copy of each. 
2) Subject aged 18 years and older : Give the subject information about the trial, answer any 
questions, obtain written informed consent from the subject, and give him / her a signed copy of the ICF. 
3) Check inclusion and exclusion criteria for eligibility (see  Section 5.2.4 and  Section 5.2.5, 
respectively).  
4) Collect relevant demographic information. 
5) Perform urine pregnancy test (if applicable).  
6) Obtain verbal medical history about the subject. 
7) Conduct a history-directed physical examination, including temperature (a physical examination conducted during the same day as part of routine clinical care may be used for this purpose). 
8) Connect to the Interactive Web Response System (IWRS) for subject identification number and randomization (see  Section 6.5 for instructions).  
9) Obtain the 10- mL pre -vaccination blood sample (see  Section 7 for detailed instructions 
regarding the handling of blood samples). If attempts to obtain the first blood dr aw are 
unsuccessful  (3 attempts) , Visit 1 can be rescheduled to a later date at which point informed 
consent and inclusion/exclusion criteria have to be re- validated. If the firs t blood draw cannot 
be obtained, the subject will be withdrawn from the trial without being vaccinated. 
10) Administer the appropriate study vaccine to the subject in the deltoid muscle. The vaccine must be administered according to the assigned study group on the side opposite to that of the 
blood sampling: 
 Group 1 = MenACYW conjugate vaccine (Lot  1) 
 Group 2 = MenACYW conjugate vaccine (Lot  2) 
 Group 3 = MenACYW conjugate vaccine (Lot  3) 
 Group 4 = Menactra
Â® 
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 32 of 80
[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 33 of 79 11) Keep the subject under observation for [ADDRESS_494807] any AE in the source 
document. 
12) Give the subject or the subjectâ€™s p arent / guardian a diary card, a thermometer, and a ruler, 
and go over the instructions for their use. 
13) Remind the subject or the subjectâ€™s parent / guardian to expect a telephone call [ADDRESS_494808] when they return f or Visit 2 at a specified date and 
time.  
14) Remind the subject or the subjectâ€™s parent / guardian to notify the site in case of an SAE.  
15) Complete the relevant CRF pages for this visit.  
Telephone Call  1 (8 to 10 days after Visit 1)  
Note : If Day  [ADDRESS_494809]â€™s parent / guardian is not available, the study staff 
should document the attempts to make contact. 
1) Record relevant information concerning the subjectâ€™s health status on the telephone contact 
[CONTACT_982]. If an SAE occurred, follow the instructions in Section 10 for reporting it.  
2) Remind the subject or the subjectâ€™s parent / guardian to do th e following: 
â€¢ Complete the D0 to D07 pages of the diary card 
â€¢ Complete the remaining pages of the diary card and bring them to Visit 2 
â€¢ Notify the site in case of an SAE  
Visit 2 (30 days [+14 days] after Visit  1): Collection of Safety Information and Blood Sa mple  
1) Review the pages of the diary card with the subject or the subjectâ€™s parent / guardian, including any AEs, medications, or therapy that occurred since vaccination. The subject or subjectâ€™s parent / guardian must return the diary card. 
2) Review the tempo rary contraindications for blood sampling (see Section 5.2.8) . 
3) Obtain the blood sample (see Section 7 for detail ed instructions regarding the handling of 
blood samples). 
4) Give the subject or the subjectâ€™s parent / guardian an MA. 
5) Complete the termination record of the CRF.  
6) If the subject or the subjectâ€™s parent / guardian does not return for Visit 2, and the diary card is not received at the site, site personnel will contact [CONTACT_29159]â€™s parent / guardian by [CONTACT_756]. During the telephone call, the subject or the subjectâ€™s parent / guardian will be reminded to return the diary card to the study site. Telephone calls will be documented on the Telephone / Interview Record. If the study personnel are unable to contact [CONTACT_29159]â€™s parent / guardian with 3 attempts, the study personnel will follow instructions given in Section 5.2.10.  
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 33 of 80
[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 34 of 79 Safety Follow -up Telephone Call 2 (180 days [+14 days] after Visit 1): Collection of SAEs and 
MAAEs  
Review the MA and ask the subject or the subjectâ€™s parent / guardian if the subject has 
experienced any SAE in the time since the vaccination that has not been reported to the study personnel and / or any MAAE. 
â€¢ If an SAE has occurred, follow the instructions in  Section 10 for reporting it . 
â€¢ If an MAAE  has occurred, follow the instructions in the Operating Guidelines. 
SAEs and AEs That Are Related to Vaccination or That Led to Discontinuation: 
At any time during the study, a subject who experiences an SAE or an AE must be followed if 
either  of the following is true: 
â€¢ The SAE or AE is considered by [CONTACT_357271], and is not 
resolved by [CONTACT_357272]â€™s participation in the trial 
â€¢ The subject has been discontinued from the trial because of the SAE or AE 
Any such subject must be followed until the condition resolves, becomes stable, or becomes 
chronic. 
5.1.[ADDRESS_494810] been obtained. 
Planned trial period - FVFS (first visit, first subject)  to LCLS (last contact, last subject) :    15 July 2016 to 30 June 2017 
Planned inclusion period - FVFS to  FVLS  
(first visit, last subject ):    15 Ju ly 2016 to 30 December 2016 
Planned vaccination period:    15 July 2016 to 30 December 2016 
Planned end of trial (LCLS) :    30 June 2017 
Planned date of final clinical study report:  [ADDRESS_494811] in either group is considered to be the end of the trial. 
5.1.6 Early Safety Data Review 
This trial will not include an early review of safety data  (i.e., no early safety review[s] of 
preliminary safety data occurring at pre-determined milestones defined in the protocol with pause 
in enrollment). However, it may be interrupted at any time if new data about the investigational product become available, and/or on advice of the Sponsor, the IECs / IRBs, or the governing regulatory authorities in the country where the trial is taking pl ace.  
If the trial is prematurely terminated or suspended, the Sponsor will promptly inform the Investigators, the IECs/IRBs, and the regulatory authorities of the reason for termination or 
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 34 of 80
[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 35 of 79 suspension. If the trial is prematurely terminated for any reason,  the Investigator will promptly 
inform the trial subjects or the subjectsâ€™ parents / guardian  and should assure appropriate therapy 
and follow-up. 
5.2 Enrollment and Retention of Trial Population  
5.2.1 Recruitment Procedures 
Before the start of the trial, the Investigator and / or study staff may contact [CONTACT_394288] / guardians of an appropriate pool of potential subjects and invite them to participate in the study. The site will ensure that any advertisements used to recr uit 
subjects (e.g. letters, pamphlets, and posters) are submitted to [COMPANY_011] Pasteur for review prior to 
submission to the IEC/ IRB for approval. 
In addition, a  potential subject who comes to a trial site for a routine visit may be invited to enroll 
in the trial, or a parent who brings a child to the trial site for a routine visit may be invited to 
enroll the child  in the trial, if eligible. Subjects may also be recruited from the general population. 
5.2.[ADDRESS_494812]â€™s parent /guardian voluntarily 
confirms his or her willingness to participate  / allow his or her child to participate  in a particular 
trial. Informed consent must be obtained before any study procedures are performed. The process 
is documented by [CONTACT_3553] a written, signed, and dated ICF. 
In this study, each subject < [ADDRESS_494813] of, the ICF that is signed by [CONTACT_7071] / guardian.  
In accordance with GCP, prior to signing and dating the consent form, the subject or  the subjectâ€™s 
parent / guardian must be informed by [CONTACT_394289], and must have sufficient time and opportunity to ask any questions.  
Prior to signing and dating the assent form, subjects < [ADDRESS_494814] whose parent / guardian cannot read will not be included 
in the trial.  
The actual I CF used at each center may differ, depending on local regulations and IEC / IRB 
requirements. However, all versions must contain the standard information found in the sample ICF provided by [CONTACT_1034]. Any change to the content of the ICF must be approved by [CONTACT_29540] / IRB prior to the form being used. 
If new information becomes available that may be relevant to the subjectâ€™s or the subjectâ€™s parentâ€™s / guardianâ€™s  willingness to continue participation in the trial, this will be communicated 
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 35 of 80
[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 36 of 79 to him / her in a timely manner. Such information will be provided via a revised ICF or an 
addendum to the original ICF. 
ICFs will be provided in duplicate, or a photocopy of the signed consent will be made. The 
original will be kept by [CONTACT_737], and the copy will be kept by [CONTACT_29159]â€™s 
parent / guardian.  
Documentation of the consent process should be recorded in the source documents. 
5.2.[ADDRESS_494815] fulfill all of the following criteria in order to be eligible for trial enrollment:  
1) Aged 10 to 55 years on the day of inclusiona 
2) Informed consent form has been signed and dated by [CONTACT_423] (aged 18 to 55 years) or 
assent form has been signed and dated by [CONTACT_394290](s) or guardian (for subjects aged 10 to < 18 years) .  
3) Subject (â‰¥  18 years) or subject (10 to <  18 years) and parent / guardian are able t o attend all 
scheduled visits and to comply with all trial procedures  
5.2.5 Exclusion Criteria  
An individual fulfilling any of the following criteria is to be excluded from trial enrollment: 
1) Subject is pregnant, or lactating, or of childbearing potential (to be considered of non-childbearing potential, a female must be pre-menarche or post- menopausal for at least [ADDRESS_494816] 4 weeks after vaccination)
b 
2) Participation in the 4 weeks preceding the trial vaccination or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure  
3) Receipt of any vaccine in the 4 weeks (28 days) preceding the trial vaccination or planned 
receipt of any vaccine prior to Visit [ADDRESS_494817] 2  weeks before or after the study investigational vaccines. This exception 
includes monovalent pandemic influenza vaccines and  multivalent influenza vaccines  
                                                
 
a  â€œ10 to 55 â€ means from the day of the 10th birthday  to the day before the 56th birthday  
b  For pre -menarche females, the young female patients will declare by [CONTACT_394291]. If a young female patient r eaches menarche during the study, then she is to be considered as a 
woman of childbearing potential from that time forward.  
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 36 of 80
[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 37 of 79 4) Previous vaccination against meningococcal disease with either the trial vaccine or another 
vaccine (i.e., mono- or polyvalent, polysaccharide, or conjugate meningococcal vaccine 
containing serogroups A, C, Y, or W; or meningococcal B vaccine) 
5) Receipt of immune globulins, blood or blood-derived products in the past 3 months 
6) Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long- term systemic corticosteroid therapy (prednisone or 
equivalent for more than [ADDRESS_494818] 3 months) 
7) History of meningococcal infection, confirmed e ither clinically, serologically, or 
microbiologically  
8) At high risk for meningococcal infection during the trial (specifically, but not limited to, subjects with persistent complement deficiency, with anatomic or functional asplenia, or subjects traveling t o countries with high endemic or epi[INVESTIGATOR_167467])  
9) Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccines used in the trial or to a vaccine containing any of the same substances  
10) Verbal report of thrombocytopenia, as reported by [CONTACT_29159]â€™s parent / guardian, contraindicating intramuscular vaccination in the Investigatorâ€™s opi[INVESTIGATOR_1649] 
11) Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindi cating intramuscular vaccination in the Investigatorâ€™s opi[INVESTIGATOR_1649]  
12) Personal history of Guillain -Barre syndrome (GBS)  
13) Personal history of an Arthus- like reaction after vaccination with a tetanus toxoid -containing 
vaccine within 10 years of the proposed study va ccination  
14) Deprived of freedom by [CONTACT_29511], or in an emergency setting, or hospi[INVESTIGATOR_29476] 
15) Current alcohol abuse or drug addiction  
16) Chronic illness that, in the opi[INVESTIGATOR_871], is at a stage where it might int erfere 
with trial conduct or completion
a 
17) Moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination or febrile illness (temperature â‰¥ 100.4Â°F). A prospective subject should not be included in the study until the condition has resolved or the febrile event has subsided 
18) Receipt of oral or injectable antibiotic therapy within [ADDRESS_494819] blood draw 
19) Identified as an Investigator or employee of the Investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (i.e., parent, 
                                                
 
a  Chronic illness may include, but is not limited to , cardiac disorders, renal disorders, auto -immune disorders, 
diabetes, psychomotor diseases, and known congenital or genetic diseases . 
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 37 of 80
[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 38 of 79 spouse, natural or adopted child) of the Investigator or employee with direct involvement in 
the proposed study 
If agreeable to the subject or the subjectâ€™s parent / guardian (as indicated in the ICF), if the subject 
has a primary physician who is not the Investigator, the site must contact [CONTACT_394292]â€™s or parentâ€™s / guardianâ€™s consent to inform him / her of the subjectâ€™s participation in the study. In addition, the site should ask this primary physician to verify exclusion criteria relating to previous therapi[INVESTIGATOR_014], such as receipt of blood products or previous vaccines. 
5.2.[ADDRESS_494820] 
and ongoing. Any such conditions will be documented in the source document. Significant 
medical history (reported as diagnosis) including conditions for which the subject is or has been followed by a physician or conditions that could resume during the course of the study or lead to an SAE or to a repetitive outpatient care will be collected in the CRF. The significant medical 
history section of the CRF contains a core list of body systems and disorders that could be used to 
prompt comprehensive reporting, as well as space for the reporting of specific conditions and illnesses.  
For each condition, the data collected will be limited to:  
â€¢ Diagnosis (this is preferable to reporting signs and symptoms) 
â€¢ Presence or absence of the condit ion at enrollment 
The reporting of signs and symptoms is strongly discouraged. 
Dates, medications, and body systems are not to be recorded, and the information collected will not  
be coded. Its purpose is to assist in the later interpretation of safety data  collected during the trial.  
5.2.[ADDRESS_494821] receive oral or injectable antibiotic therapy within 3 days prior to the second 
blood draw, the Investigator will postpone that blood draw until it has been 3 days (72 hours) 
since the subject last received oral or injectable antibiotic therapy. Postponement must still be within the timeframe for blood draw (30 to 44 days after vaccination at D0). If postponement 
would result in the sample collection falling outside of this timeframe, the blood sample should be collected without postponement, and it should be documented appropriately that the s ample was 
taken less than 3  days after stoppi[INVESTIGATOR_29479].  
5.2.9 Conditions for Withdrawal 
Subjects / parents  / guardians will be informed that they have the right to withdraw / withdraw 
their child from the trial at any time.  
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 38 of 80
[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page [ADDRESS_494822] may be withdrawn from the study: 
â€¢ At the discretion of the Investigator or Sponsor due to safety concerns (withdrawal) without 
the subjectâ€™s permission  
â€¢ At the request of the subject or the subjectâ€™s parent / guardian (dropout)  
The following will result in automatic withdrawal or exclusion of a subject from the study: 
â€¢ Significant non-compliance with the protocol, based on the Investigatorâ€™s judgment 
The reason for a withdrawal or dropout should be clearly documented in the source documents 
and on the CRF.  
The Investigat or must determine whether voluntary withdrawal is due to safety concerns (in 
which case, the reason for discontinuation will be noted as â€œSAEâ€ or â€œother AEâ€ as appropriate) 
or for another reason. 
Withdrawn subjects will not be replaced. 
5.2.[ADDRESS_494823] to Follow- up Procedures 
In the case of subjects who fail to return for a follow-up examination, documented reasonable 
effort (i.e., documented telephone calls and certified mail) should be undertaken to locate or recall them, or at least to determine their health status  while fully respecting their rights. These efforts 
should be documented in the CRF and in the source documents. 
5.2.[ADDRESS_494824] significant (refer to the CRF completion guidelines for additional details and 
examples) : 
â€¢ Serious adverse event:  To be used when a subject drops out of or is withdrawn from the 
study by [CONTACT_190623], as defined in Section [IP_ADDRESS]. 
â€¢ Other adverse event:  To be used when a subject drops out of or is withdrawn from the study 
by [CONTACT_357277], as defined in 
Section [IP_ADDRESS]. 
â€¢ Non-compliance with proto col: To be used when the Investigator withdraws a subject from 
the study because of failure to follow the protocol, including when it is retrospectively discovered that a subject did not fulfill the eligibility criteria. The Investigator will provide a comment as to the specific cause of non -compliance.  
â€¢ Lost to follow -up: To be used when the Investigator withdraws a subject from the study 
because of failure to establish contact, as outlined in  Section 5.2.10. The Investigator will 
provide  documentation that contact [CONTACT_188854] (i.e., return of unsigned certified letter 
receipt).  
â€¢ Voluntary withdrawal not due to an adverse event:  To be used when a subject drops out of 
the study for any reason other than those listed above. 
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 39 of 80
[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page [ADDRESS_494825] one dose of the 
study vaccine( s) has been administered, the subject will not be discontinued from the trial and will 
be followed for safety assessment (and may be followed for immunogenicity as sessment, if 
applicable). However, no additional vaccination will be administered.  
All pregnancy cases should be reported if they occurred during the study, and during the 6-month 
follow-up period or if the start date of the pregnancy cannot be determined. To report the pregnancy case,  the Investigator must fill out a Pregnancy Reporting Form in the electronic data 
capture (EDC) system  and send it to the Sponsor within [ADDRESS_494826] to obtain information about the outcomeâ€”i.e., details about the delivery and the newborn, or about pregnancy terminationâ€”and must update the electronic  Pregnancy Reporting Form. This information should be provided to the Sponsor 
within 1 month of delivery. 
Pregnancy itself is not considered an AE, but any complications during pregnancy are to be considered as AEs, and in some cases could be considered SAEs. Spontaneous abortions, fetal death, stillbirth, and congenital anomalies reported in the ba by [CONTACT_35338], 
and the information should be provided to the Global PharmacoVigilance (GPV) Department 
regardless of when the SAE occurs (e.g., even after the end of the trial).  
5.3 Safety Emergency Call  
If, as per the Investigatorâ€™s judgment, a subject experiences a medical emergency, the Investigator may contact [CONTACT_1034]â€™s RMO for advice on trial related medical question or problem. If the RMO is not available, then the Investigator may contact [CONTACT_29555] - available [ADDRESS_494827] ace the need to report  an SAE. The investigator is still required to 
follow the protocol defined process for reporting SAEs to GPV (p lease refer to  Section 10). 
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 40 of 80
[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page [ADDRESS_494828] the earlier version. All substantial amendments (e.g., that affect the conduct of the trial or the safety of subjects) 
require IEC  / IRB approval, and must also be forwarded to regulatory authorities. 
An administrative  amendment to a protocol is one that modifies some admi nistrative or logistical 
aspect of the trial but does not affect its design or objectives or have an impact on the subjectsâ€™ safety. Administrative changes do not require IEC  / IRB approval; however, the IEC / IRB must be 
notified whenever one is made.  
The Investigator is responsible for ensuring that changes to an approved trial, during the period 
for which IEC / IRB approval has already been given, are not initiated without IEC / IRB review 
and approval, except to eliminate apparent immediate hazards to subjects. 
5.[ADDRESS_494829] resulting from this or any other trials become available; or for administrative reasons; or on advice of the Sponsor, the Investigators, and / or the IECs  / IRBs. If the trial is prematurely terminated or suspended, the 
Sponsor shall promptly inform the Investigators, the regulatory authorities, and the IECs / IRBs of 
the reason for termination or suspension, as specified by [CONTACT_150062].  
The Investigator shall promptly inform the trial subjects or the trial subjectsâ€™ parents / guardians and assure appropriate therapy and / or follow-up for them. 
[ADDRESS_494830]  
MenACYW conjugate vaccine: Meningococcal Polysaccharide (Serogroups  A, C, Y, and W) 
Tetanus Toxoid Conjugate Vaccine ([COMPANY_011] Pasteur Inc., Swiftwater, PA, [LOCATION_003]) 
Form:   Liquid solution 
Dose:   0.5 milliliter (mL)  
Route:   IM 
Batch number:  3 Lots ( UD18368, UD18364, UD18365) 
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 41 of 80
[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 42 of 79 [IP_ADDRESS] Composition  
Each 0.5 mL dose of MenACYW conjugate vaccine is formulated in sodium acetate buffered 
saline solution to contain the following components: 
Meningococcal capsular polysaccharides:  
Serogroup A ...................................................................................................................... 10 Âµg 
Serogroup C ...................................................................................................................... 10 Âµg 
Serogroup Y ...................................................................................................................... 10 Âµg 
Serogroup W  ..................................................................................................................... 10 Âµg 
Tetanus toxoid protein carrier ........................................................................ approximately 65 Âµg 
[IP_ADDRESS] Preparation and Administration  
MenACYW conjugate vaccine is supplied in single- dose (0.5 mL) vials.  
Prior to administration, all study products must be inspected visually f or cracks, broken seals, 
correct label content (see  Section 6.3.1) , and extraneous particulate matter and / or discoloration, 
whenever solution and container permit. If any of these conditions exists, the vaccine must not be 
administered.  A replacement dose is to be used, and the event is to be reported to the Sponsor. 
The rubber stopper should not be removed from any of the vaccine vials. 
One dose (0.5 mL) of MenACYW conjugate vaccine will be administered IM into the deltoid 
muscle of the arm. The site of injection should be prepared with a suitable antiseptic. After 
administration of the vaccine, the used syringe and needle will be disposed of in accordance with currently estab lished guidelines. 
Subjects must be kept under observation for 30 minutes after vaccination to ensure their safety, and any reactions during this period will be documented in the CRF. Appropriate medical equipment and emergency medications, including epi[INVESTIGATOR_238] (1:1000), must be available on site in the event of an anaphylactic or other immediate allergic reaction.  
[IP_ADDRESS] Dose Selection and Timing  
Subjects in Group [ADDRESS_494831]  
Menactra
Â®: Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid 
Conjugate V accine ([COMPANY_011] Pasteur Inc., Swiftwater, PA, [LOCATION_003])  
Form :  S olution for injection  
Dose :  0.5 mL 
Route :  IM 
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 42 of 80
[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 43 of 79 Batch number :  U5462AB (provided by [CONTACT_1034]) 
[IP_ADDRESS] Composition  
Each 0.5 mL dose of vaccine is formulated in sodium phosphate buffered isotonic sodium 
chloride solution to contain the following ingredients: 
Serogroup A ............................................................................................................................. 4 Âµg 
Serogroup C ............................................................................................................................. 4 Âµg  
Serogroup Y ............................................................................................................................. 4 Âµg 
Serogroup W -135 .................................................................................................................... 4 Âµg  
Diphtheria toxoid protein carrier ................................................................... approximately 48 Âµg  
[IP_ADDRESS] Preparation and Administration  
MenactraÂ® is supplied in single- dose (0.5 mL) vials.  One dose of MenactraÂ® will be administered 
IM into the deltoid muscle of the arm.  
See the MenactraÂ® package insert  (34). The procedures for preparing and administering 
MenactraÂ® are the same as those described for the trial product in  Section [IP_ADDRESS]. 
[IP_ADDRESS] Dose Selection and Timing  
Subjects in Group 4 will receive 1 dose of MenactraÂ® on D0. 
6.[ADDRESS_494832] Logistics  
6.3.1 Labeling and Packaging 
MenACYW conjugate vaccine will be supplied in single -dose vials, labeled and packaged 
accor ding to national regulations. The information on the label and packaging will include: 
â€¢ Study code 
â€¢ Product name 
â€¢ Pharmaceutical form  
â€¢ Dosage 
â€¢ Storage conditions 
â€¢ Name [CONTACT_271162] 
â€¢ The statement: â€œCaution: New Drug â€“ Limited by [CONTACT_12201]â€  
A commercial lot of MenactraÂ® in single- dose (0.5 mL) vials  will be supplied by [CONTACT_394293]., with commercial labeling on the vial  and investigational packaging. 
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 43 of 80
[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page [ADDRESS_494833] Shipment, Storage, and Accountability  
[IP_ADDRESS] Product Shipment  
The Clinical Logistics Coordinator or designee will contact [CONTACT_29517] a designee in order 
to determine the dates and times of delivery of products. 
Each vaccine shipment will include a temperature-monitoring device to verify maintenance of the 
cold chain during transit. On delivery of the product to the site, the person in charge of product receipt will follow the instructions given in the Operating Guidelines, including checking that the cold chain was maintained during shipment (i.e., verification of the temperature recorders). If there is an indication that the cold chain was broken, this person should immediately quarantine the product, alert the [COMPANY_011] Pasteur  representative, and request authorization from [COMPANY_011] Pasteur  
to use the product. 
[IP_ADDRESS] Product Storage  
The I nvestigator will be personally responsible for product management or will designate a 
qualified staff member to assume this responsibility.  
At the site, products must be kept in a secure place with restricted access. Vaccines will be stored 
in a refrigerat or at a temperature ranging from +2Â°C to +8Â°C. The vaccines must not be frozen. 
The temperature must be monitored and documented (see the Operating Guidelines) for the entire time that the vaccine is at the trial site. In case of accidental freezing or dis ruption of the cold 
chain, vaccines must not be administered and must be quarantined, and the Investigator or 
authorized designee should contact [CONTACT_35340].  
[IP_ADDRESS] Product Accountability  
The person in charge of product management at the site will maintain records of product delivery 
to the trial site, product inventory at the site, the dose(s) given to each subject, and the disposal of or return to the Sponsor of unused doses. 
The necessary information on the product labels is to be entered into the source document and the 
CRF. If applicable, information may also be entered into the subjectâ€™s vaccination card. 
The Sponsorâ€™s monitoring staff will verify the trial siteâ€™s product accountability records against 
the record  of administered doses in the CRFs and the communication from the IWRS  (if 
applicable). 
In case of any expected or potential shortage of product during the trial, the Investigator or an 
authorized designee should alert the [COMPANY_011] Pasteur representative as soon as possible, so that a 
shipment of extra doses can be arranged.  
6.3.3 Replacement Doses 
If a replacement dose is required (e.g., because the syringe broke or particulate matter was observed in the syringe), the site personnel must either connect to the IWRS  to receive the new 
dose allocation, or follow the instructions given in the Operating Guidelines. 
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 44 of 80
[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 45 of 79 6.3.4 Disposal of Unused Products  
Unused or wasted products will be returned to the Sponsor in accordance with the instructions in 
the Operating Guidelines. Produc t accountability will be verified throughout the trial period.  
6.3.5 Recall of Products  
If the Sponsor makes a decision to launch a retrieval procedure, the Investigator(s) will be informed of what needs to be done. 
6.[ADDRESS_494834](s) experiencing the SAE.  
The blind can be broken by [CONTACT_29517] a sub- investigator (me dical doctor only
a), by 
[CONTACT_357280]-breaking procedures described in the 
Operating Guidelines. Once the emergency has been addressed by [CONTACT_779], the Investigator must notify the [COMPANY_011] Pasteur RMO if a subjectâ€™s code was broken. All contact [CONTACT_357281]. 
A request for the code to be broken may be made: 
â€¢ by [CONTACT_394294] ( ICH) E2A. In this case, the code will be broken 
only for the subject(s) in question. The information resulting from code- breaking (i.e., the 
subjectâ€™s vaccine or group assignment) will not be communicated to either the Investigator or 
the immediate team working on the study, except for the GPV representative.  
The IEC  / IRB must be notified of the code-breaking. All documentation pertaining to the event 
must be retained in the siteâ€™s study records and in the [COMPANY_011] Pasteur  files. Any intentional or 
unintentional code-breaking must be reported, documented, and explained, and the name [CONTACT_29562]. 
6.5 Randomization and Allocation Procedures  
On the day of enrollment, subjects who meet the inclusion/exclusion criteria and sign the ICF (subjects aged 18 to 55 years) or sign the assent form and whose parent / guardian signs the ICF 
                                                
 
a  according to local regulations  
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 45 of 80
[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 46 of 79 (subjects aged 10 to 17 years) will be randomly assigned to Groups 1 through 4 in a 3:3:3:[ADDRESS_494835] approximately 900 subjects 
(400 subjects 10 to 17 years old and 500 subjects 1 8 to 55 years old) and Group [ADDRESS_494836] 
approximately 600 subjects (300 subjects 10 to 17 years old and 300 subjects 1 8 to 55 years old) . 
Site staff will connect to the IWRS , enter the identification and security information, and confirm 
a minimal amount of data in response to IWRS prompts. The IWRS will then provide the group 
assignment and have the site staff  confirm it. The full detailed procedures for group allocation are 
described in the Operating Guidelines. If the subject is not eligible to participate in the trial, then 
the information will only be recorded on the subject recruitment log.  
Subject numbers that are assigned by [CONTACT_394295] 8 -digit string (a [ADDRESS_494837] identifier connected by â€œ-â€). For example, Subject 001-
00001is the first subject enrolled in center number 1. Subject numbers s hould not be reassigned 
for any reason. 
6.6 Treatment Compliance  
The following measures will ensure that the vaccine doses administered comply with those planned, and that any non- compliance is documented so that it can be accounted for in the data analyses:  
â€¢ All vaccinations will be administered by [CONTACT_357283]  
â€¢ The person in charge of product management at the site will maintain accountability records 
of product delivery to the trial site, product inventory at the site, dose(s) given to each subject, and the disposal of unused or wasted doses 
6.7 Concomitant Medications  and Other Therapi[INVESTIGATOR_35274], ongoing medications including other therapi[INVESTIGATOR_014] e.g., blood products, should be recorded in the source document as well as new medications pr escribed for new 
medical conditions / AEs during trial participation.  
Documentation in the CRF of concomitant medication will be limited to specific categories of 
medication of interest beginning on the day of vaccination. This may include medication s of 
interest that were started prior to the day of vaccination. 
Reportable medications  will be collected in the CRF from the day of vaccination to the end of the 
solicited and unsolicited follow -up period (e.g., 30  day safety follow -up) as they may impact the 
response to the vaccination and impact the consistency of the information collected on 
concomitant medications at any vaccination. 
The â€œreportableâ€ medications are distributed according to 3 categories. These are:  
â€¢ Category 1 antipyretics, analgesics, non -steroidal anti -inflammatory drugs (NSAIDs), 
corticosteroids, and other immune modulators.  
Note: inhaled and topi[INVESTIGATOR_357242]. 
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 46 of 80
[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 47 of 79 â€¢ Category 2: Reportable medications used to define the Per -Protocol Analysis Set (PPAS). For 
example:  
â€¢ Influenza and other non- study vaccines: Influenza vaccine in the [ADDRESS_494838]â€™s termination from the trial and any other vaccines 
(other than the study vaccine) in the [ADDRESS_494839]â€™s termination from the trial  
â€¢ Immune globulins, blood or blood-derived products: used in the [ADDRESS_494840] blood draw 
â€¢ Immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy: used 
in the 6 months preceding the trial vaccination and the 4 weeks following the trial vaccination 
â€¢ Category 3: Oral or injectable antibiotics, which may interfere with bioassays used for 
antibody testing when taken before a blood draw. 
â€¢ The period of collection should be within [ADDRESS_494841] scheduled blood draw. 
Note: Inhaled and topi[INVESTIGATOR_8163] (drops, creams, or ointments) should not be captured. 
The information reported in the CRF for each reported medication wil l be limited to:  
â€¢ Trade name 
â€¢ Given as treatment or as prophylaxis 
â€¢ Medication category  
â€¢ Start and stop dates  
Dosage and administration route will not be recorded. Homeopathic medication will not be 
recorded.  Topi[INVESTIGATOR_357243]. 
The fact that a medication was given in response to an AE will be captured in the â€œAction Takenâ€ 
column of the AE only. No details will be recorded in the concomitant medication module of the CRF unless  the medication received belongs to one of the prelisted categori es. Medications will 
not be coded. 
[ADDRESS_494842]â€™s identity; will verify  the assigned subject â€™s number on the pre- printed label that 
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 47 of 80
[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page [ADDRESS_494843]â€™s number and the sampling stage; and will attach the label to the tube. Blood 
is to be taken from the limb opposite to the one that will be used for vaccination. 
7.2 Sample Preparation  
Detailed instructions on how to prepare blood samples for assessment of antibody response are 
contained in the Operating Guidelines provided to the site. An overview of the procedures is provided here. 
Following the blood draw, the sample tubes are to be left undisturbed, positioned vertically and 
not shaken, for a minimum of 1 hour and a maximum of 24 hours in order to allow the blood to clot. Samples can be stored at room temperature for up to  2 hours; beyond [ADDRESS_494844] be 
refrigerated at a temperature of +2Â°C to +8Â°C and must be centrifuged within a maximum of [ADDRESS_494845]â€™s number and the sampling stage or visit number. 
The subjectâ€™s number and the date of sampling, the number of aliquots obtained, the date and time 
of preparation, and the subjectâ€™s consent for future use of his / her samples are to be specified on a sample identification list and recorded in the source document. Space is provided on this list for comments on the quality of samples. 
7.3 Sample Storage and Shipment  
Durin g storage, serum tubes are to be kept in a freezer whose temperature is set and maintained at 
-20Â°C or below. The temperature will be monitored and documented on the appropriate form during the entire trial. If it rises above -10Â°C for any period of time, the Clinical Logistics 
Coordinator must be notified. See the Operating Guidelines for further details. 
Shipments to the laboratories will be made only after appropriate monitoring, and following 
notification of the Clinical Logistics Coordinator. Sera will  be shipped frozen, using dry ice to 
maintain them in a frozen state, in the packaging container provided by [CONTACT_21440] . Again, 
temperatures will be monitored. Shipments must be compliant with the International Air 
Transport Association ( IATA ) 602 regulations. 
Samples will be shipped to Global Clinical Immunology (GCI) at [COMPANY_011] Pasteur . The address is 
provided in the Operating Guidelines.  
7.4 Future Use of Stored Serum Samples for Research  
Any unused part of the serum samples will be securely stored at the S anofi Pasteur  serology 
laboratory ( GCI) for at least [ADDRESS_494846] license approval in the relevant market areas has 
been obtained for the vaccine being tested. 
The subjects or the subjectsâ€™ parents / guardians will be asked to indicate in the ICF whether they 
will permit the future use of any unused stored serum samples for other tests. If they refuse 
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 48 of 80
[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 49 of 79 permission, the samples will not be used for any testing other than that directly related to this 
study. If they agree to this use, they will not be paid for giving permission. (Anonymity of 
samples will be ensured.) The aim of any possible future research is unknown today, and may not 
be related to this particular study. It may be to improve the knowledge of vaccines or infectious diseases, or to improve laboratory methods. Genetic tests will never be performed on these samples without individual informed consent. 
8 Clinical Supplies  
[COMPANY_011] Pasteur will supply the trial sites with protocols, ICFs (including Assent forms), CRFs, 
SAE reporting forms, pregnancy reporting forms, diary cards, memory aids, and other trial documents, as well as with the following trial materials: all study vaccines , blood collection tubes, 
cryotubes, cryotube storage boxes, cryotube labels, temperature recorders, shippi[INVESTIGATOR_35275], rulers, and digital thermometers.  
The means for performing EDC will be defined by [CONTACT_35346] . If a computer is provided by 
[CONTACT_35346] , it will be retrieved at the end of the trial.  
The Investigator will supply all vaccination supplies, phlebotomy, and centrifugation equipment, including biohazard and / or safety supplies. The biohazard and safety supplies include needles 
and syringes, examination gloves, laboratory coats, sharps disposal containers, and absorbent countertop paper. The site wi ll ensure that all biohazard wastes are autoclaved and disposed of in 
accordance with local practices. The Investigator will also supply appropriate space in a temperature -monitored refrigerator for the storage of the products and for the blood samples, and 
appropriate space in a temperature -monitored freezer for serum aliquots. 
In the event that additional supplies are required, study staff must contact [CONTACT_35346] , 
indicating the quantity required. Contact [CONTACT_35347]. They must allow approximately [ADDRESS_494847] the supplies sent to their site.  
9 Endpoints and Assessment Methods  
9.1 Primary Endpoints and Assessment Methods  
9.1.1 Immunogenicity  
[IP_ADDRESS] Immunogenicity Endpoints  
The primary endpoints for the evaluation of immunogenicity are: 
1) Geometric mean titer ratios (GMTRs) of antibodies against meningococcal serogroups A, C, 
Y, and W measured by [CONTACT_357256] 30 days (+14 days) after vaccination between lots for immune lot consistency  
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 49 of 80
[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 50 of 79 2) Vaccine seroresponse of men ingococcal serogroups A, C, Y, and W measured by [CONTACT_394296] (D0, before vaccination) and 30  days (+14  days) after vaccination for 
immune non- inferiority between MenACYW conjugate vaccine and MenactraÂ® (Groups 1 - 3 
pooled versus Group 4) 
[IP_ADDRESS] Immunogenicity Assessment Method  
 
 
 
 
 
 
 
 
 
 
 
 
 
9.1.2 Sa
fety 
There are no primary objectives for safety.  
9.1.3 Efficacy 
No clinical efficacy data will be obtained in the trial.  
9.2 Secondary Endpoints and Assessment Methods  
9.2.1 Immunogenicity  
[IP_ADDRESS] Immunogenicity Endpoints  
The secondary endpoints for immunogenicity are: 
1) Vaccine seroresponse of meningococcal serogroups A, C, Y, and W measured by [CONTACT_394296] (D0, before vaccination) and 30  days (+14  days) after vaccination for 
immune non- inferiority between MenACYW conjugate vaccine and MenactraÂ® adult study 
participants (Groups  1b, 2b, and 3b pooled versus Group 4b) 
2) Vaccine se roresponse of meningococcal serogroups A, C, Y, and W measured by [CONTACT_394296] (D0, before vaccination) and 30  days (+14  days) after vaccination for 
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 50 of 80

[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 51 of 79 immune non- inferiority between MenACYW conjugate vaccine and MenactraÂ® adolescent 
study participants (Group 1, 2a, and 3a pooled versus Group 4a) 
3) Vaccine seroresponse of meningococcal serogroups A, C, Y, and W measured by [CONTACT_357256] 
30 days (+14  days) following the administration of MenACYW conjugate vaccine (Groups 1, 
2, and 3) 
4) GMTRs of antibodies again st meningococcal serogroups A, C, Y, and W measured by [CONTACT_394297] (Groups 1 - 3 pooled) and Menactra
Â® (Group 4) 
[IP_ADDRESS] Immunogenicity Assessment Methods  
The immunogenicity hSBA assessment method for the secondary e ndpoints is the same as that 
presented in Section [IP_ADDRESS]. 
9.2.2 Safety 
There are no secondary objectives for safety.  
9.2.3 Efficacy 
No clinical efficacy data will be obtained in the trial.  
9.3 Observational Endpoints and Assessment Methods  
9.3.1 Immunogenicity  
[IP_ADDRESS] Immunogenicity Endpoints  
The observational endpoints for immunogenicity are: 
Antibody titers against meningococcal serogroups A, C, Y, and W measured by [CONTACT_394298] (rSBA) assessed at baseline (D0, before 
vaccination) and 30 days (+14 days) after vaccination in a subset of subjects for all groups 
[IP_ADDRESS] Immunogenicity Assessment Method  
 
 
 
 
 
 
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 51 of 80

[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 52 of 79   
 
 
 
 
 
 
 
9.3.2 Safety 
[IP_ADDRESS] Safety Definitions  
The following definitions are taken from the ICH E2A Guideline for Clinical Safety Data 
Management: Definitions and Standards for Expedited Reporting. 
Adverse Event (AE):  
An AE is any untoward medical occurrence in a patient or clinical investigation subject 
administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom or disease temporally associated with the use of a medici nal product, whether or not considered related to the medicinal 
product.  
Therefore an AE may be:  
â€¢ A new illness  
â€¢ The worsening of a concomitant illness 
â€¢ An effect of the vaccination, including the comparator 
â€¢ A combination of the above 
All AEs include serious and non- serious AEs. 
Surgical procedures are not AE s; they are the action taken to treat a medical condition. It is the 
condition leading to the action taken that is the AE  (if it occurs during the trial period).  
Pre-existing medical conditions are not to be reported as AEs. However, if a pre- existing 
condition worsens in frequency or intensity, or if in the assessment of the treating physician there 
is a change in its clinical significance, this change should be reported as an AE (exacerbation). This appl ies equally to recurring epi[INVESTIGATOR_35276] -existing conditions (e.g., asthma) if the 
frequency or intensity increases post-vaccination. 
                                                
 
a  T60: Time of incubation duration of 60 minutes  
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 52 of 80

[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 53 of 79 Serious Adverse Event (SAE):  
Serious  and severe are not synonymous. The term severe is often used to describe the intensit y of 
a specific event as corresponding to Grade  3. This is not the same as serious which is based on 
patient / event outcome or action criteria usually associated with events that pose a threat to a 
patientâ€™s life or functioning. Seriousness, not severity, serves as a guide for defining regulatory reporting obligations. 
An SAE is any untoward medical occurrence that at any dose  
â€¢ Results in death  
â€¢ Is life -threateninga 
â€¢ Requires inpatient hospi[INVESTIGATOR_35277] 
â€¢ Results in p ersistent or significant disability  / incapacityc 
â€¢ Is a congenital anomaly  / birth defect  
â€¢ Is an important medical eventd 
Adverse Reaction:  
All noxious and unintended responses to a medicinal product related to any dose should be 
considered adverse reactions (AR) . 
(The phrase â€œresponses to a medicinal productâ€ means that a causal relationship between a medicinal product and an AE  is at least a reasonable possibility)  
Unexpected Adverse Reaction (UAR):  
An unexpected adverse reaction is an AR , the nature or severity of which is not consistent with 
the applicable product information (e.g., Investigatorâ€™s Brochure for an unapproved investigational medicinal product).  
The following additional definitions are used by [CONTACT_35346]: 
Solicited Reaction:  
A solicited reaction is an event that is prelisted  in the CRF. The assessment of these AEs post-
vaccination is mandatory. A solicited reaction is defined by a combination of: 
                                                
 
a  The term â€œlife -threateningâ€ refers to an event in which the subject was at risk of death at the time of the event; it does not refer 
to an event which hypothetically might have caused death if it were more severe.  
b  All medical events leading to hospi[INVESTIGATOR_167480], with the exception of: hospi[INVESTIGATOR_394278] -patient treatment with no hospi[INVESTIGATOR_059].  
c  â€œPersistent or significant disability or incapacityâ€ means that there is a substantial disruption of a personâ€™s ability to carry out 
normal life functions.  
d  Medical and scientific judgment should be exercised in deciding whether expedited reporting is appropriate in other situations, such as important medical events that may not be immediately life -threatening or result in death or hospi[INVESTIGATOR_394279]. These should also usually be considered serious. Examples of such events include allergic bronchospasm requiring 
intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient 
hospi[INVESTIGATOR_059], or the development of drug dependency or drug abuse, GBS, new onset diabetes, or autoimmune disease . 
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 53 of 80
[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 54 of 79 â€¢ Symptom and 
â€¢ Onset post- vaccination  
Examples of solicited reactions include injection site pain between D0 and D07 post-vaccination 
or headache between D0 and D07. 
A solicited reaction is therefore an AR observed and reported under the conditions ( symptom and 
onset) prelisted (i.e., solicited) in the CRF  and considered as related to vaccination . 
Unsolicited AE  / AR: 
An unsolicited AE is an observed AE that does not fulfill the conditions prelisted in the CRF in 
terms of diagnosis and / or onset post-vaccination, i.e., excluding solicited reactions, e.g., if 
headache between D0 and D07 is a solicited  reaction  (i.e., prelisted in the CRF), then a headache 
starting on D [ADDRESS_494848] ion: 
An injection site reactiona is an AR at and around the injection site. Injection site reactions are 
commonly inflammatory reactions.  Systemic AE:  
Systemic AEs are all AEs that are not injection site reactions. They therefore include systemic 
manifestations such as headache, fever, as well as localized or topi[INVESTIGATOR_394280], e.g., erythema that is localized but that is not at the injection 
site. 
Medically -Attended Adverse Event (MAAE) 
An MAAE is def ined, for the purpose of this study, as a new onset of a condition that prompts the 
subject or subjectâ€™s parent/guardian to seek unplanned medical advice at a physicianâ€™s office or Emergency Department. This definition excludes pre- planned medical office v isits for routine 
pediatric check -ups or follow-up visits of chronic conditions with an onset prior to entry in the 
study. Physician contact [CONTACT_357288] a physician office visit for the purpose of MAAE collection. The outcome of the physician contact (whether it results in a prescription or not) will not be considered as a basis for reporting the event as an MAAE and all contacts should be reported. Sufficient data should be collected for the event to allow an assessment of the causality and diagnosis, if possible.  
                                                
 
a  All injection site AEs are considered to be related to vaccination  and are therefore all injection site reactions . 
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 54 of 80
[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 55 of 79 [IP_ADDRESS] Safety Endpoints  
The observational endpoints for the evaluation of safety are : 
â€¢ Occurrence, nature (Medical Dictionary for Regulatory Activities [MedDRA] preferred term), 
duration, intensity, and relationship to vaccination of any unsolicited systemic AEs reported in the 30 minutes after vaccination. 
â€¢ Occurrence, time of onset, number of days of occurrence, intensity, action taken, and whether 
the reaction led to early termination from the study, of solicited ( prelisted in the subjectâ€™s 
diary card and electronic case report form [CRF]) injection site reactions occurring up to 7 days after vaccination.  
â€¢ Occurrence, time of onset, number of days of occurrence, intensity, action taken, and whether 
the reaction led to early termination from the study, of solicited (prelisted in the subjectâ€™s diary card and CRF) systemic reactions occurring up to 7 days after vaccination. 
â€¢ Occurrence, nature (MedDRA preferred term), time of onset, duration, intensity, action taken, 
relationship to vaccination (for systemic AEs only), and whether the event led to early 
termination from the study, of unsolicited AEs up to Visit 2 after vaccination.  
â€¢ Occurrence, nature (MedDRA preferred term), time of onset, duration, seriousness criteria, 
relationship to vaccination, outcome, and whether the SAE led to early termination from the study, of SAEs throughout the trial. 
â€¢ Occurrence, nature (MedDRA preferred term), time of onset, duration, seriousness, 
relationship to vac cination, and outcome for M AAE s from Visit [ADDRESS_494849]. MAAE s will be collected as unsolicited AEs up to Visit 2.  
[IP_ADDRESS] Safety Assessment Methods 
At Visit 2, the Investigator or a delegate will ask the subject or parent  / guardian about any 
solicited reactions and unsolicited AEs recorded in the diary card, as well as about any other AEs 
that may have occurred since the previous visit. All relevant data will be transcribed into the CRF according to the instructions provided by [CONTACT_1034]. 
[IP_ADDRESS].[ADDRESS_494850]-vaccination surveillance should be documented in the source document. Any AE that occurs during this period will be noted on the source document and recorded in the CRF, as follows: 
â€¢ Any unsolicited systemic AE occur ring during the first [ADDRESS_494851]- vaccination will be 
recorded on the CRF as immediate unsolicited systemic AE .  
â€¢ Solicited and unsolicited injection site reactions an d solicited systemic reactions will be 
recorded and analyzed as starting on the day of vaccination.  
â€¢ Any SAE occurred during the first [ADDRESS_494852] as any other SAE and to the Sponsor, according to the procedures described in Section 10.  
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 55 of 80
[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 56 of 79 [IP_ADDRESS].2 Reactogenicity (Solicited Reactions From Day 0 to Day 07 After Vaccination)  
After  vaccination, subjects or parents / guardians will be provided with a safety diary card, a 
digital thermometer, and a flexible ruler, and will be instructed how to use them. T he following 
items will be recorded by [CONTACT_35349] 
7 days (i.e., D0 to D07) until re solution: 
â€¢ Daily temperature, with the route by [CONTACT_35350] 
â€¢ Daily measurement or intensity grade of all other solicited injection site and systemic 
reactions  
â€¢ Action taken for each event, if any (e.g., medication) 
The action taken by [CONTACT_394299] / guardian to treat any solicited reactions will be 
classified in the CRF using the following scale:  
0: None 
1: Medication (self -medication with an existing prescription or over- the-counter medication) 
2: Health care provider contact (no new medication prescribed)  
3:  Health care provider contact [CONTACT_190638] a new medication (health care provider 
instructed subject to take a new medication, either an over -the-counter medication or one 
requiring a written prescription)  
4: Hospi[INVESTIGATOR_059] (inpatient)  
Subjects or parents / guardians  will be contact[CONTACT_5143] [ADDRESS_494853] is made. Every telephone attempt and its outcome will be documented in the source document. 
Table 9.1 and  Table 9.2 present, respectively, the injection site reactions and systemic reactions 
that are prelisted in the diary cards and CRF, together with the intensity scales.  
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 56 of 80
[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 57 of 79 Table 9.1: Solicited injection site reactions: terminology , definitions , and intensity scales  
CRF term 
(MedDRA lowest level term [LLT])  Injection site pain  Injection site erythema  Injection site swelling  
Diary card term Pain Redness  Swelling  
Definition  Presence of a redness including the approximate point of needle entry Swelling at or near the injection site  
Swelling or edema is caused by a fluid 
infiltration in tissue or cavity and, depending 
on the space available for the fluid to disperse, swelling may be either soft (typi[INVESTIGATOR_897]) or firm (less typi[INVESTIGATOR_2855]) to touch and 
thus can be best described by [CONTACT_394300]* 
 Grade 1: No interference with activity 
Grade 2: Some interference  with activity 
Grade 3: Significant; prevents daily activity  Grade 1: â‰¥ 25 to â‰¤ 50 mm 
Grade 2: â‰¥ 51 to â‰¤ 100 mm 
Grade 3: > 100 mm Grade 1: â‰¥ 25 to â‰¤ 50 mm 
Grade 2: â‰¥ 51 to â‰¤ 100 mm 
Grade 3: > 100 mm 
* For the subjective reaction of pain, subjects or paren ts / guardians  will record the intensity level (Grade  1, 2, or 3) in the diary card. For the measurable reactions of redness and 
swelling, they will record just the size of the reaction, and the classification as Grade  1, 2, or 3 will be assigned at the time of the statistical analysis  
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
                
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 57 of 80
[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 58 of 79 Table 9.2: Solicited systemic reactions: terminology , definitions , and intensity scales  
CRF term 
(MedDRA LLT)  Fever Headache  Malaise Myalgia 
Diary card term  Temperature  Headach e Feeling unwell  Muscle aches and pains  
Definition Elevation of temperature to â‰¥ 100.4Â°F  
(â‰¥ 38.0Â°C ) Pain or discomfort in the head or 
scalp. Does not include migraine.  General ill feeling.  
Malaise is a generalized feeling of discomfort, illness, or lack o f well -
being that can be associated with a disease state. It can be accompanied by a sensation of exhaustion or 
inadequate energy to accomplish 
usual activities.  Muscle aches and pains are common and can involve more than one muscle at the same time. Muscle pain can also involve the soft tissues that 
surround muscles. These structures, 
which are often referred to as connective tissues, include ligaments, 
tendons, and fascia (thick bands of 
tendons). 
Does not apply to muscle pain at the 
injection site which should be 
reported as injection site pain.  
Intensity scale* Grade  1: â‰¥ 100.4Â°F to â‰¤ 101.1Â°F , 
or â‰¥ 38.0Â°C to â‰¤  38.4Â°C  Grade  1: No interference with activity  Grade 1: No interference with activity  Grade  1: No interference with activity  
 Grade  2: â‰¥ 101.2Â°F to â‰¤ 102.0Â°F , 
or â‰¥ 38.5Â°C to â‰¤  38.9Â°C  Grade  2: Some interference with 
activity  Grade 2: Some interference with 
activity  Grade  2: Some interference with 
activity  
 Grade  3: â‰¥ 102.1Â°F  
or â‰¥ 39.0Â°C  Grade  3: Significant; prevents daily 
activity  Grade  3: Signifi cant; prevents daily 
activity  Grade  3: Significant; prevents daily 
activity  
*  For all reactions but fever, subjects or parents / guardians  will record the intensity level (Grade  1, 2, or 3) in the diary card. For fever, they will record the body temperat ure, and the 
classification as Grade 1, 2, or 3 will be assigned at the time of the statistical analysis.  
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
                
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 58 of 80
[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 59 of 79 Important Notes for the Accurate Assessment of Temperature:  
Subjects or parents / guardians are to measure body temperature once per day, preferably always 
at the same time. The optimal time for measurement is the evening, when body temperature is the 
highest. Temperature is also to be measured at the time of any apparent fever. The observed  daily 
temperature and the route of measurement are to be reco rded in the  diary card , and the highest 
temperature will be recorded by [CONTACT_29558]. The preferred route for this trial is oral.  Pre-
vaccination temperature is also systematically collected  by [CONTACT_357292]. Tympanic therm ometers must not be used.  
[IP_ADDRESS].3 Unsolicited Non-serious Adverse Events From Day 0 to Day 30 After Vaccination  
In addition to recording solicited reactions, subjects or parents / guardians  will be instructed to 
record any other medical events that may occur during the 30-day period after vaccination. Space 
will be provided in the diary card for this purpose.  
For each unsolicited non- serious AE, the following information is to be recorded: 
â€¢ Start and stop datesa  
â€¢ Intensity of the event: 
â€¢ For measurable unsolicited non-serious AEs that are part of the l ist of solicited reactions, the 
size of the AE as well as the temperature for fever will be collected and analyzed based on the 
corresponding scale used for solicited reactions (see Table 9.1 and Table 9.2) 
â€¢ Other unsolicited non-serious AEs will be classified according to the following intensity scale:  
â€¢ Grade  1: No interference with activity  
â€¢ Grade  2: Some interference with activity  
â€¢ Grade  3: Significant; prevents daily activity  
â€¢ Action taken for each AE , if any (e.g., medication) 
The action taken by [CONTACT_11867] / guardian to treat any unsolicited AEs  will be classified 
in the CRF using the following scale: 
0: None 
1: Medication (self -medication with an existing prescription or over- the-counter medication) 
2: Health care provider contact (no new medication prescribed)  
3:  Health care provider contact [CONTACT_190638] a new medication (health care provider 
instructed subject to take a new medication, either an over -the-counter medication or one 
requiring a written prescription)  
                                                 
a The stop date of all related AEs will be actively solicited. For other events, the investigator will provide the stop 
date when it becomes available. AEs for which no stop date was obtained during the  course of the trial will be 
considered as ongoing at the end of the trial.  
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 59 of 80
[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 60 of 79 â€¢ Whether the AE led to discontinuation 
â€¢ Whether the AE was related to vaccination (for unsolicited systemic AEs)  
[IP_ADDRESS].4 Serious Adverse Events 
Information on SAEs will be collected and assessed throughout the trial, from inclusion  until 
180 days (+14 days) after vaccination.  
Any SAE occurring at any time during the trial will be reported by [CONTACT_394301]. All information 
concerning the SAE is to be reported, either as part of the initial reporting or during follow-up reporting if relevant information became available later (e.g., outcome, medical history, re sults of 
investigations, copy of hospi[INVESTIGATOR_35286]. The Investigator will assess the causal relationship 
between the SAE and the investigational product as either â€œNot relatedâ€ or â€œRelatedâ€, as described in  Section 10.4. 
See Section 10 for further details on SAE reporting. 
[IP_ADDRESS].5  
Not applicable. 
[IP_ADDRESS].6 Medically-Attended Adverse Events 
MAAE  information will be collected throughout the study. MAAEs that occur from Visit 1 (D0) 
to Visit 2 (D30[+14days]) will be recorded as unsolicited AEs on the diary card as part of all 
unsolicited AEs collected for this post-vaccination period. MAAE s that occur from Visit 2 
(D30  [+14 days]) to D180 (+14 days) will be recorded as such in the MA. A MAAE that occurs 
within the study period but meets the definition of an SAE should be reported only on the SAE Reporting Form, but not on the MAAE page of the CRF. The Investigator will assess the causal relationship between the MAAE and the investigational or study product as either â€œNot relatedâ€ or â€œRelatedâ€, as described in  Section [IP_ADDRESS].7. 
[IP_ADDRESS].7 Assessment of Causality   
The Investigator will assess the causal relationship  between each unsolicited systemic AE and 
vaccination as either not related or related, based on the following definitions
a: 
0: Not related â€“ The AE is clearly  / most probably caused by [CONTACT_357295]â€™s underlying condition, therapeutic intervention, or concomitant therapy; or the delay between vaccination and the onset of the AE is incompatible with a causal relationship; or the AE started before the vacc ination (screening phase , if applicable ) 
                                                
 
a  ICH Guidelines, Clinical Safety Data Management E2A  
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 60 of 80

[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 61 of 79 1:  Related â€“ There is a â€œreasonable possibilityâ€ that the AE was caused by [CONTACT_190644], 
meaning that there is evidence or arguments to suggest a causal relationship  
Note: By [CONTACT_559], all injection site AEs (solicited and unsolicited) and all solicited systemic 
reaction s are considered to be related to vaccination and referred to as reactions, and therefore do 
not require the Investigatorâ€™s opi[INVESTIGATOR_125611]. 
AEs likely to be related to the product, whether serious or not, that persist at the end of the trial 
will be followed up by [CONTACT_125630]â€™s condition. The Investigator will inform the Sponsor of the date of final disappearance of the event. 
9.3.[ADDRESS_494854] document all SAEs regardless of causal relationship, and notify the Sponsor and the Clinical Research Associate ( CRA) within the notification timelines stated in the following 
sections. The Investigator will give access and provide the Sponsor and the CRA with all necessary information to  allow the Sponsor to conduct a detailed analysis of the safety of the 
investigational product(s). It is the responsibility of the Investigator to request all necessary documentation (e.g., medi cal records, discharge summary,  autopsy) in order to provide 
comprehensive safety information. All relevant information must then be transcribed into the electronic Serious Adverse E vent (eSAE) Form . 
10.[ADDRESS_494855]â€™s participation in the trial or experiment must be reported within 24 hours to the Sponsorâ€™s GPV Department and to the CRA. Every SAE must be reported, even if the Investigator considers that it is not related to the vaccine. The SAE form must be signed by a licensed physician (M.D. or D.O .) for whom th e task is listed on the Study Task Delegation and 
Signature [CONTACT_357309].  
The Investigator must complete the â€œeSAE Formâ€ in the EDC application. After validation, an e-mail alert will automatically be sent to the GPV mailbox, the CRA and the CTL . This message 
will include the country, the study code, the subject number, whether the report is initial or a follow-up, the diagnosis and / or symptoms, the seriousness criteria, the relationship, if related  
and the outcome, if fatal. 
If the EDC system is unavailable, the site must notify the Sponsor using the paper version of the 
SAE Reporting Form, as follows: 
The Investigator must complete the SAE Reporting Form, check off the â€œInitial Reporting Formâ€ 
box, and send it to the Sponsor by [CONTACT_29553] (preferably by [CONTACT_3719] e- mail): 
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 61 of 80
6DQRIL3DVWHXU 0(7
Â±0HQ$&<:&RQMXJDWH9DFFLQH
&RQILGHQWLDO3URSULHWDU\,QIRUPDWLRQ
3DJHRIx%\ID[WRWKHIROORZLQJQXPEHU 
x,Q3')IRUPDWWRWKHIROORZLQJHPDLODGGUHVVXVLQJDPHWKRGR IWUDQVPLVVLRQWKDW
LQFOXGHVSDVVZRUGSURWHFWLRQ VHHWKH2SHUDWLQJ
*XLGHOLQHVIRUGLUHFWLRQVRQKRZ WRVHQGDSDVVZRUGSURWHFWHGH PDLO
x%\H[SUHVVPDLOWRWKHIROORZLQJDGGUHVV6DQRIL3DVWHXU,QF 
5HFHSWLRQDQG7ULDJHÂ±&DVH0DQDJHPHQW
*OREDO3KDUPDFR9LJLODQFH0DLO'URS''LVFRYHU\'ULYH6ZLIWZDWHU3$
:KHQWKHV\VWHPEHFRPHVDYDLODEO HWKH,QYHVWLJDWRUPXVWWUDQVF ULEHWKHLQIRUPDWLRQIURPWKH
SDSHUYHUVLRQRIWKHH6$()RUPLQWRWKH('&V\VWHP
,IWKHUHLVQHHGIRUXUJHQWFRQV XOWDWLRQWKH,QYHVWLJDWRULVW RFRQWDFWWKH502,IWKH502FDQQRW
EHUHDFKHGWKH,QYHVWLJDWRUPD\FRQWDFWWKH&DOO&HQWHUDVGHV FULEHGLQ6HFWLRQ 
)ROORZXS5HSRUWLQJE\WKH,QYHVWLJDWRU
7KHH6$()RUPFRPSOHWHGLQL WLDOO\PXVWEHXSGDWHGZLWKLQKRX UVDIWHUWKH,QYHVWLJDWRUKDV
EHFRPHDZDUHRIDQ\QHZUHOHYDQWLQIRUPDWLRQFRQFHUQLQJWKH6$( HJRXWFRPHSUHFLVH
GHVFULSWLRQRIPHGLFDO KLVWRU\UHVXOWVRIW KHLQYHVWLJDWLRQ $IWHUYDOLGDWLRQDQHPDLODOHUWZLOO
EHVHQWDXWRPDWLFDOO\WRWKH*3 9'HSDUWPHQWDQGWRWKH&5$$OO UHOHYDQWLQIRUPDWLRQPXVWEH
LQFOXGHGGLUHFWO\LQWKHH6$()RUP&RSLHVRIGRFXPHQWVHJ PHGLFDOUHFRUGVGLVFKDUJH
VX[COMPANY_003]U\DXWRSV\PD\EHUHTXHVWHGE\WKH*39'HSDUWPHQW
7KHDQRQ\PLW\RIWKHVXEMHFWPXVWDOZD\VEHUHVSHFWHGZKHQIRUZ DUGLQJWKLVLQIRUPDWLRQ
5HSRUWLQJRI6$(V2FFXUULQJ$IWHUD6XEMHFW+DV&RPSOHWHGWKH6 WXG\
$Q\6$(WKDWRFFXUVDIWHUDV XEMHFWKDVFRPSOHWHGWKHVWXG\EXW WKDWLVOLNHO\WREHUHODWHGWRWKH
SURGXFWRUWRWKHH[SHULPHQWPXVWDOVREHUHSRUWHGDVVRRQDVS RVVLEOH,QVXFKDFDVHWKH
UHSRUWLQJSURFHGXUHWREHIROORZH GLVLGHQWLFDOWRWKDWGHVFULE HGLQ6HFWLRQ 
$VVHVVPHQWRI&DXVDOLW\
7KHFDXVDOUHODWLRQVKLSEHWZHH QWKH6$(DQGWKHSURGXFWZLOOIL UVWEHHYDOXDWHGE\WKH
,QYHVWLJDWRUXVLQJWKHIROORZLQJGHILQLWLRQV
1RWUHODWHG 7KH$(LVFOHDUO\PRVWSU REDEO\FDXVHGE\RWKHUHWLRORJLHV VXFKDVDQ
XQGHUO\LQJFRQGLWLRQWKHUDSHXWLFLQWHUYHQWLRQRUFRQFRPLWDQW WKHUDS\RUWKHGHOD\EHWZHHQ
YDFFLQDWLRQDQGWKHRQVHWRIWKH6$(LVLQFRPSDWLEOHZLWKDFDX VDOUHODWLRQVKLSRUWKH6$(
VWDUWHGEHIRUHWKHYDFFLQDWLRQVFUHHQLQJSKDVHLIDSSOLFDEOH 
5HODWHG 7KHUHLVDÂ³UHDVRQDEOHSRVVLELOLW\Â´WKDWWKH6$(ZDVFDXVHGE\ WKHYDFFLQDWLRQ
PHDQLQJWKDWWKHUHLVHYLGHQFHRU DUJXPHQWVWRVXJJHVWDFDXVDO UHODWLRQVKLS6DQRIL3DVWHXU 

&RQILGHQWLDO3URSULHWDU\,QIRUPDWLRQ
0(7
Â±0HQ$&<:&RQMXJDWH9DFFLQH 3URWRFRO9HUVLRQ
3DJHRIPII
PII
6DQRIL3DVWHXU 0(7
Â±0HQ$&<:&RQMXJDWH9DFFLQH
&RQILGHQWLDO3URSULHWDU\,QIRUPDWLRQ
3DJHRI,&+*XLGHOLQHV&OLQLFDO6DI HW\'DWD0DQDJHPHQW($
)ROORZLQJWKLVWKH6SRQVRUÂ¶V3 URGXFW6DIHW\2IILFHU362ZLOO DOVRDVVHVVWKHFDXVDOUHODWLRQVKLS
WRWKHSURGXFWEDVHGRQWKHDYD LODEOHLQIRUPDWLRQDQGFXUUHQW PHGLFDONQRZOHGJH
7KHGHFLVLRQWRPRGLI\RUGLVFRQ WLQXHWKHWULDOPD\EHPDGHDIW HUPXWXDODJUHHPHQWEHWZHHQWKH
6SRQVRUDQGWKH,QYHVWLJDWRUV
5HSRUWLQJ6$(VWR+HDOWK $XWKRULWLHVDQG,(&V,5%V
7KH6SRQVRUZLOOLQIRUPWKHUHOHYDQWKHDOWKDXWKRULWLHVRIDQ\ UHSRUWDEOH6$(VDFFRUGLQJWRWKH
ORFDOUHJXODWRU\UHTXLUHPHQWV5 HSRUWLQJWRWKHKHDOWKDXWKRULW LHVZLOOEHDFFRUGLQJWRWKH
6SRQVRUÂ¶VVWDQGDUGRSH UDWLQJSURFHGXUHV
7KH6SRQVRUÂ¶V502   ZLOOQR WLI\WKH,QYHVWLJDWRUVLQZULWL QJ
RIWKHRFFXUUHQFHRIDQ\UHSRUWDEO H6$(V7KH,QYHVWLJDWRUV6 SRQVRUZLOOEHUHVSRQVLEOHIRU
LQIRUPLQJWKH,(&VRU,5%VWKDW UHYLHZHGWKHWULDOSURWRFRO
'DWD&ROOHFWLRQDQG0DQDJHPHQW
'DWD&ROOHFWLRQDQG&5)&RPSOHWLRQ
,QGLYLGXDOVDIHW\GLDU\FDUGVV SHFLILFDOO\GHVLJQHGIRUWKLVW ULDOE\WKH6SRQVRUDQGSURYLGHGWR
WKHVWXG\VLWHVZLOOEHJLYHQWRVW XG\SDUWLFLSDQWVIRUWKHUH FRUGLQJRIGDLO\VDIHW\LQIRUPDWLRQDV
GHVFULEHGLQ 6HFWLRQ 7KHVHGLDU\FDUGVZLOOLQFOXGHSUHOLVWHGWHUPVDQGLQWHQVLW\V FDOHV
VHH7DEOHDQG7DEOHDVZHOODVDUHDVIRUIUHHWH[WWRFDSWXUHDGGLWLRQDOVDIHW\L QIRUPDWLRQ
RURWKHUUHOHYDQWGHWDLOV6XEMHFW VRUSDUHQWVJXDUGLDQVZLOO DOVREHSURYLGHGZLWKUXOHUVIRU
PHDVXULQJWKHVL]HRILQMHFWLRQVLWHUHDFWLRQVDQGZLWKVWDQGD UGGLJLWDOWKHUPRPHWHUVIRU
PHDVXULQJGDLO\WHPSHUDWXUHV7RHQVXUHFRQVLVWHQF\RIUHSRUWLQ JWKHVWXG\VLWHV ZLOOLQVWUXFW
VXEMHFWVRUSDUHQWVJXDUGLDQVRQKRZWRFRUUHFWO\XVHWKHVHW RROV
7KHPRQWKIROORZXSZLOOEHGRQH E\LQWHUYLHZLQJVXEMHFWVRU SDUHQWVJXDUGLDQVHLWKHUGXULQJ
DYLVLWRURYHUWKHWHOHSKRQHXV LQJDTXHVWLRQQDLUHWRFDSWXUH 6$(VDQG$(VRISDUWLFXODULQWHUHVW
LIDSSOLFDEOH$Q0$Z LOOEHSURYLGHGWRWKHV XEMHFWVDWWKHSU HFHGLQJWULDOYLVLWWRKHOSWKHP
UHFRUGLQIRUPDWLRQRQHYHQWVRFFX UULQJEHWZHHQWKLVYLVLWDQGW KHPRQWKIROORZXS
5HOHYDQWLQIRUPDWLRQZLOOEHWUDQVFULEHGLQWRWKH&5)$Q\6$(V FDSWXUHGGXULQJWKLVPRQWK
IROORZXSSHULRGZLOOEHUHSRUWHGD QGIROORZHGXSDVSHUWKHQR UPDOSURFHVVIRUUHSRUWLQJ6$(V
7KHFOLQLFDOWHDPPD\GHFLGHWR UHSODFHWKH0$ E\DGLDU\FDUG LIDIROORZXSYLVLWLVSODQQHGIRU
WKHVXEMHFWV
$WVSHFLILHGLQWHUYDOVWKH, QYHVWLJDWRURUDQDXWKRUL]HGGHVLJ QHHZLOOLQWHUYLHZWKHVXEMHFWVRU
SDUHQWVJXDUGLDQVWRFROOHFWW KHLQIRUPDWLRQUHFRUGHGLQWKH GLDU\FDUGDQGZLOODWWHPSWWRFODULI\
DQ\WKLQJWKDWLVLQFRPSOHWHRUXQ FOHDU$OOFOLQLFDOWULDOLQIR UPDWLRQJDWKHUHGE\W KHVWXG\VLWHZLOO
EHUHSRUWHGHOHFWURQLFDOO\E\WKH, QYHVWLJDWRURU DXWKRUL]HGGH VLJQHHXVLQJDZHEEDVHG&5)
$Q\LQIRUPDWLRQWKDWZDVQRWGRF XPHQWHGLQWKHGLDU\FDUGZLOO ILUVWEHFDSWXUHGLQWKHVRXUFH6DQRIL3DVWHXU 

&RQILGHQWLDO3URSULHWDU\,QIRUPDWLRQ
0(7
Â±0HQ$&<:&RQMXJDWH9DFFLQH 3URWRFRO9HUVLRQ
3DJHRIPII PI[INVESTIGATOR_394274]43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 64 of 79 document and then reported electronically.) The CRF has been designed specifically f or this trial 
under the responsibility of the Sponsor, using a validated Electronic Records / Electronic 
Signature-compliant platform (21 CFR Part 11). 
To ensure the correct and consistent completion of the CRFs, the Sponsor or authorized 
representative wi ll provide all necessary tools, instructions, and training to all site staff involved 
in data entry prior to study start. Additional instructional documents such as training manuals and completion guidelines will be provided to assist with data entry durin g the course of the trial.  
Upon completion of training, each user requiring access to the EDC system will be issued a unique username [CONTACT_2383]. In the event of a change in trial personnel, each newly assigned individual will receive a unique username [CONTACT_2383]; the username [CONTACT_35395] a previous user may not be reissued. If any trial personnel leave the study, the Investigator is responsible for informing the Sponsor immediately so that their access is deactivated. An audit trail will be initiated in the EDC system at the time of the first data entry in order to track all modifications and to ensure database integrity. 
The Investigator is responsible for the timeliness, completeness, and accuracy of the information 
in the CRFs; must provide explanations for all missing information; and must sign the CRF using an e- signature.  
11.2 Data Management  
Management of Clinical Data  
Data generated during the trial will be managed following two different processes:  
â€¢ Clinical data, defined as all data reported in the CRF, and laboratory data will be handled by [CONTACT_1034]â€™s Clinical Data Management (CDM) platform or authorized representative.  
â€¢ Data pertaining to SAEs, which are reported by [CONTACT_190649], will be handled by [CONTACT_1034]â€™s GPV  Department.  
During the trial,  clinical data reported in the CRFs will be integrated into the clinical database 
under the responsibility of the [COMPANY_011] Pasteur  CDM platform. Data monitoring at the sites and 
quality control in the form of co mputerized logic and / or consistency checks will be 
systematically applied in order to detect errors or omissions. In addition, data reviews may be 
performed several times by [CONTACT_1034]â€™s staff in the course of the trial. Any questions pertaining 
to the reported clinical data will be submitted to the investigator for resolution using the EDC 
system. Each step of this process will be monitored through the implementation of individual passwords to maintain appropriate database access and to ensure database integrity.  
The validation of the immunogenicity data will be performed at the laboratory level following the 
laboratoryâ€™s procedures. Information from the laboratory will be checked for consistency before integration into the clinical database.  
After integration of all corrections in the complete set of data, and after the SAE information available from CDM and the GPV Department has been reconciled, the database will be released for 
statistical analysis.  
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 64 of 80
[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 65 of 79 SAE Data Management  
During the trial, data pertaining to SAEs reported on eSAE Forms will be integrated into the 
Sponsorâ€™s centralized GPV  database.  
Upon receipt of an eSAE Form, the data will be entered into the GPV database after a duplicate 
check. Each SAE case will be assigned a case identification number. Each case will be entered in the GPV database and assessed by [CONTACT_35375]. Assessment of related cases will be done in collaboration with the PSO and the RMO. Follow-up information concerning a completed case will be entered into the GPV database, and a new version of the case will be created.  
The information pertaining to SAEs in the GPV  database will be reconciled with that in the 
clinical database.  
11.[ADDRESS_494856] will be continuously monitored by [CONTACT_1034]. Periodic safety data review will be perfo rmed by [CONTACT_1034]â€™s SMT. For all periodic safety reviews, 
blinded safety data will be provided to the Sponsorâ€™s SMT. 
12 Statistical Methods and Determination of Sample Size  
12.1 Statistical Methods  
Clinical data will be analyzed under the responsibility of the B iostatistics Platform of the Sponsor. 
A statistical analysis plan (SAP) will be written and peer reviewed before any analyses. In accordance with the protocol, the SAP will describe all analyses to be performed under the responsibility of the Sponsor and all the conventions to be taken. 
12.1.1 Hypotheses and Statistica l Methods for Primary Objective s 
[IP_ADDRESS] Primary Objective [ADDRESS_494857] meningococcal serogroups A, C, Y, and W in Groups 1, 2, and 3 are equivalent. 
Null hypothesis (H
0): GMT (Gi) / GMT (Gj) â‰¤ 1/2 or GMT (Gi) / GMT (Gj) â‰¥ 2 for any i â‰  j  
Alternative hypothesis (H 1): 1/2 < GMT (Gi) / GMT (Gj) < 2 for all i â‰  j  
GMT (Gi) and GMT (Gj) are the GMTs of antibodies against the meningococcal serogroups A, C, Y, 
and W for the ith and jth lots, respectively.  Each of the antigens of A, C, Y, and W serogroups 
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 65 of 80
[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 66 of 79 will be tested separately. If the 2 -sided 95% confidence interval  (CI) of the ratio of the GMTs is 
> 1/2 and < 2 for each antigen, the non- equivalence assumption will be rejected.  
Assuming that log 10 trans formation of the data follows a normal distribution, the log 10 (data) will 
be used for the statistical analysis, then antilog transformations will be applied to the results of 
calculations, in order to provide the results in terms of GMTs.  
For each of the equivalence hypotheses using the GMT ratios, the statistical methodology will be based on the use of the 2-sided 95% CI of difference in means of post-vaccination log
10 
transformed titers between the 2 groups with normal approximation. 
[IP_ADDRESS] Primary Objective 2  
Non-inferiority of MenACYW Conjugate Vaccine Compared to MenactraÂ® in Terms of hSBA 
Vaccine Seroresponse  
Thirty days after the administration of MenACYW conjugate vaccine or MenactraÂ®, the 
percentages of subjects who achieve an hSBA vaccine seroresponsea for meningococcal 
serogroups A, C, Y, and W in Groups 1, 2, and 3 combined are non-inferior to the corresponding percentages in Group  4. 
Null hypothesis (H
0): p(G123)  - p (G4) â‰¤ -10% 
Alternative hypothesis (H 1): p(G123)  - p ( G4) > -10% 
where p(G123)  and p (G4) are the percentages of subjects who achieve an hSBA vaccine seroresponse 
in Groups 1 - 3 pooled and Group 4, respectively. Each of the serogroups A, C, Y, and W will be tested separately. If the lower limit of the 2 -sided 95% CI  of the difference between  the 
2 proportions is > -10%, the inferiority assumption will be rejected. 
For the 4 non- inferiority hypotheses using the seroresponse rates, the CI of the difference in 
proportions will be computed using the Wilson Score method without continuity correction  
(35). The overall non- inferiority of this objective will be demonstrated if all 4 in dividual null 
hypotheses are rejected.  
                                                
 
a hSBA vaccine  seroresponse for serogroups A, C, Y, and W is defined as:  
â€¢ For a subject with a pre- vaccination titer <  1:8, th e post -vaccination titer must be â‰¥  1:16.  
â€¢ For a subject with a pre- vaccination titer â‰¥  1:8, the post -vaccination titer must be at least 4 -fold greater than the 
pre-vaccination titer.  
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 66 of 80
[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 67 of 79 12.1.2 Hypotheses and Statistical Methods for Secondary Objectives 
[IP_ADDRESS] Secondary Objective 1  
Non-inferiority of MenACYW Conjugate Vaccine Compared to MenactraÂ® in Terms of hSBA 
Vaccine Seroresponse in the Adult Population ( 18 to 55 Years Old) 
Thirty days after the administration of MenACYW conjugate vaccine or MenactraÂ®, the 
percentages of subjects who achieve an hSBA  vaccine seroresponsea for meningococcal 
serogroups A, C, Y, and W in Groups 1b, 2b, and 3b combined are non- infer ior to the 
corresponding percentages in Group 4b. 
Null hypothesis (H 0): p(G123)  - p (G4) â‰¤ -10% 
Alternative hypothesis (H 1): p(G123)  - p ( G4) > -10% 
where p(G123)  and p (G4) are the percentages of subjects who achieve an hSBA vaccine seroresponse 
in Groups 1b, 2b, and 3b pooled and Group 4b, respectively. Each of the serogroups A, C, Y, and 
W w ill be tested separately. If the lower limit of the 2 -sided 95% CI of the difference between the 
2 proportions is > -10%, the inferiority assumption will be rejected. 
For the 4 non- inferiority hypotheses using the seroresponse rates, the CI of the difference in 
proportions will be computed using the Wilson Score method without continuity correction  
(35). The overall non- inferiority of this objective will be demonstrated if all 4 individual null 
hypotheses are rejected.  
[IP_ADDRESS] Secondary Objective 2  
Non-inferiority of MenACYW Conjugate Vaccine Compared to MenactraÂ® in Terms of hSBA 
Vaccine Seroresponse in the Adolescent Population (10 to 17 Years Old) 
Thirty days after the administration of MenACYW conjugate vaccine or MenactraÂ®, the 
percentages of subjects who achieve an hSBA vaccine seroresponsea for meningococcal 
serogroups A, C, Y, and W in Groups 1a, 2a, and 3a combined are non- inferior to the 
corresponding percentages in Group 4a. 
Null hypothesis (H 0): p(G123)  - p (G4) â‰¤ -10% 
Alternate hypothesis (H 1): p(G123)  - p (G4) > -10% 
where p(G123)  and p (G4) are the percentages of subjects who achieve an hSB A vaccine seroresponse 
in Groups 1a, 2a, and 3a pooled and Group 4a, respectively. Each of the serogroups A, C, Y, and 
W will be tested separately. If the lower limit of the 2 -sided 95% CI of the difference between the 
2 proportions is > - 10%, the inferior ity assumption will be rejected.  
                                                 
a  hSBA vaccine  seroresponse for serogroups A, C, Y, and W is defined as:  
â€¢ For a subject with a pre- vaccination titer <  1:8, the post -vaccination titer must be â‰¥  1:16.  
â€¢ For a subject with a pre- vaccination titer â‰¥  1:8, the post -vaccination titer must be at least 4 -fold greater than the 
pre-vaccination titer.  
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 67 of 80
[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 68 of 79 For the 4 non-inferiority hypothesis using the seroresponse rates, the CI of the difference in 
proportions will be computed using the Wilson Score method without continuity correction (35). 
The overall non- inferiority of this objective will be demonstrated if all 4 individual null 
hypotheses are rejected.  
[IP_ADDRESS] Secondary Objective 3 
Comparison of 3 MenACYW Conjugate Vaccine Lots in Terms of hSBA Vaccine Seroresponse  
The difference in percentages of subjects who achieve an hSBA vaccine seroresponsea 30 days 
after the administration of MenACYW conjugate vaccine for men ingococcal serogroups A, C, Y, 
and W in Groups 1, 2, and 3 will be calculated for each comparison and 95% CI will be provided. 
The CI of the difference in proportions will be computed using the Wilson Score method without 
continuity correction  (35). 
[IP_ADDRESS] Secondary Objective 4 
Comparison of MenACYW Conjugate Vaccine to MenactraÂ® in Terms of hSBA GMTs  
The ratio of GMTs of meningococcal serogroups A, C, Y, and W between the MenACYW conjugate vaccine Groups 1- 3 pooled (Lots 1, 2, and 3 combined) and the Menactra
Â® Group 4 
30 days after the administration of vaccine will be calculated and 95% CI will be  provided. 
Assuming that log 10 transformation of the data follows a normal distribution, the log 10 (data) will 
be used for the statistical analysis, then antilog transformations will be applied to the results of calculations, in order to provide the result s in terms of GMTs.  
For each of the GMT ratios, the statistical methodology will be based on the use of the 2-sided 95% CI of difference in means of post-vaccination log
10 transformed titers between the 2  groups 
with normal approximation. 
12.1.3 Statistical Meth ods for Observational Objectives 
No hypotheses will be tested. Descriptive statistics will be presented.  
[IP_ADDRESS] Immunogenicity  
Descriptive statistics will be provided for the antibody titers against meningococcal serogroups 
contained in each lot of MenACYW conjuga te vaccine and in MenactraÂ®.  
In general, categorical variables will be summarized and presented by [CONTACT_211261], percentages, and CIs. The 95% CIs of point estimates will be calculated using the normal approximation for quantitative data and the exact binomial distribution (Clopper -Pearson method) 
                                                
 
a  hSBA vaccine  seroresponse for serogroups A, C, Y, and W is defined as:  
â€¢ For a subject with a pre- vaccination titer <  1:8, the post -vaccination titer must be â‰¥  1:16.  
â€¢ For a subject with a pre- vaccination titer â‰¥  1:8, the post -vaccination titer must be at least 4 -fold greater than the 
pre-vaccination titer.  
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 68 of 80
[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 69 of 79 for percentages  (36). For GMTs, 95% CIs of point estimates will be calculated using normal 
approximation assuming they are log- normally distributed. Reverse cumulative distribution curve 
(RCDC) figures will be provided for the antibody titers against meningococcal serogroups. 
In summary, descrip tive analyses on A, C, Y, and W serogroups will include but not be limited to: 
â€¢ hSBA GMT s and 95% CI at each time point for each group 
â€¢ hSBA titer distribution and RCDC  
â€¢ Proportion of subjects with hSBA titer â‰¥ 1:4 and â‰¥ 1:8 and 95% CI at D0 and D30 for each 
group 
â€¢ Proportion of subjects with hSBA titer â‰¥ 4- fold rise from pre -vaccination to post -
vaccination, and 95% CI 
â€¢ rSBA GMT s and 95% CI at each time point in a subset of 100 subjects in  each group 
â€¢ rSBA titer distribution and RCDC  
â€¢ Proportion of subjects with rSBA titer â‰¥ 1:8 and â‰¥ 1:128 and 95% CI at D0 and D30 in a 
subset of 100 subjects in  each group 
â€¢ Proportion of subjects with rSBA titer â‰¥ 4- fold rise from pre -vaccination to post -
vaccination and 95% CI  
â€¢ Vaccine seroresponsea against meningococcal serogroups A, C, Y, and W measured by 
[CONTACT_394285] 95% CI  
[IP_ADDRESS] Safety 
Safety results will be described for subjects in all study groups. The main parameters for the 
safety endpoints will be described by 95% CIs (based  on the Clopper -Pearson method). 
The frequency and percentage of subjects who had solicited injection site and systemic reactions 
and their 95% CIs will be provided. These events will be tabulated by [CONTACT_394302], as well as by [CONTACT_394303].  
Unsolicited AEs will be collected, coded, and summarized by [CONTACT_14340]. For each unsolicited AE, the number of subjects with at least one instance of that event will be reported. Unsolicited AEs will also be tabulated by [CONTACT_394303]. 
12.2 Analysis Sets  
Three analysis sets will be used: the Full Analysis Set (FAS), the PPAS, and the Safety Analysis Set (SafAS).  
                                                
 
a  rSBA vaccine seroresponse is defined as a post -vaccination titer â‰¥  1:32 for subj ects with pre -vaccination rSBA 
titer < 1:8, or a post -vaccination titer â‰¥  4 times the pre -vaccination titer for subjects with pre -vaccination rSBA 
titer â‰¥ 1:8.  
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 69 of 80
[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page [ADDRESS_494858] o ne of the following 
relevant protocol deviations will be excluded from the PPAS: 
â€¢ Subject did not meet all protocol- specified inclusion criteria or met at least one of the 
protocol- specified exclusion criteria  
â€¢ Subject did not receive vaccine  
â€¢ Subject received a vaccine other than the one that he / she was randomized to receive 
â€¢ Preparation and / or administration of vaccine was not done as per-protocol 
â€¢ Subject did not receive vaccine in the proper time window 
â€¢ Subject did not provide post -dose serology sample in the proper time window or a post-dose 
serology sample was not drawn.  
â€¢ Subject received a protocol -prohibited Category 2 or Category 3 therapy / medication / 
vaccine  
â€¢ Subjectâ€™s serology sample did not produce a valid test result 
â€¢ Subject had other protocol violations that affected the subjectâ€™s immune response, as 
determined by [CONTACT_357303].  
12.2.4 Populations Used in Analyses  
The primary immunogenicity analyses will be performed on the PPAS, and will be confirmed on 
the FAS. In the FAS, subjects will be analyzed by [CONTACT_394304]. 
All safety analyses will be performed on the SafAS. Subjects will be analyzed according to the 
vaccine they actually received . 
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 70 of 80
[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page [ADDRESS_494859] or search for outliers will be performed.  
In order to appropriately manage extreme values (undetectable responses < LLOQ and â‰¥ upper 
limit of quantitation [ULOQ]), the f ollowing computational rule is applied to the values provided 
in the clinical database for each blood sample drawn for analysis purposes:  
â€¢ If a value is < LLOQ, then use the computed value LLOQ/2  
â€¢ If a value is between â‰¥ LLOQ and < ULOQ, then use the value 
â€¢ If a value is â‰¥ ULOQ, then use the computed value ULOQ 
The derived endpoint of fold- rise is computed as follows for extreme values, to minimize the 
numerator and maximizes the denominator: 
â€¢ If the baseline computed value is < LLOQ and the post -baseline computed value is <  LLOQ 
then the fold- rise is 1  
â€¢ If the baseline computed value is â‰¥ LLOQ and the post -baseline computed value is â‰¥ LLOQ 
then the fold- rise is post- baseline computed value / baseline computed value  
â€¢ If the baseline computed value is â‰¥ LLOQ and the post -baseline computed value is < LLOQ 
then the fold- rise is (LLOQ/2) / baseline computed value  
â€¢ If the baseline computed value is < LLOQ and the post -baseline computed value is â‰¥ LLOQ 
then the fold- rise is post- baseline computed value /LLOQ  
12.3.3 Efficacy 
Not applicable. 
12.4 Interim / Preliminary  Analysis 
No interim / preliminary analyses are planned.  
12.5 Determination of Sample Size and Power Calculation  
 
 
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 71 of 80

[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 72 of 79  
 
 
 
 
 
     
     
     
     
     
     
 
 
 
     
     
     
     
     
     
 
13 Ethical and Legal Issues and Investigat or / Sponsor Responsibilities  
13.[ADDRESS_494860] of the Trial  / Good Clinical Practice  
The conduct of this trial will be consistent with the standards established by [CONTACT_35378]  / or national 
regulations and directives.  
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 72 of 80

[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 73 of 79 13.2 Source Data and Source Documents 
â€œSource dataâ€ are the data contained in source documents. Source documents are original 
documents or certified copi[INVESTIGATOR_014], and include, but are not limited to, diary cards, m edical and 
hospi[INVESTIGATOR_1097], screening logs, informed consent / assent forms, telephone contact [CONTACT_29543], and 
worksheets. The purpose of trial source documents is to document the existence of subjects and to substantiate the integrity of the trial data collected. Investigators must maintain source documents so that they are accurate, complete, legible, and up to date. 
For missing or discrepant data on a diary card, the study coordinator will obtain verbal clarification  
from the subject, enter the response into the â€œinvestigatorâ€™s commentâ€  page of the diary card, and 
transfer the information to the CRF. The subject pre -screening  log should list all individuals contact[CONTACT_357305], regardless of the outcome.  
The Investigator must print
a any electronic records on an ongoing basis, sign and date them 
immediately after creation, and keep the printouts on file as source documents that can be verified 
by [CONTACT_167547]. Any later changes of an electronic record require the record to be re -printed, dated (with an indication of the date of change), and 
signed. Such records must also be kept together with the original printed copy. 
13.[ADDRESS_494861] Records  
Prior to initiation of the trial, the Investigator will sign a fully executed confidentiality agreement with [COMPANY_011] Pasteur . 
[COMPANY_011] Pasteur personnel (or designates), the IECs / IRBs, and regulatory agencies, including the 
Food and Drug Administration ( FDA), require direct access to all study records, and will treat 
these documents in a confidential manner. 
In the event a subjectâ€™s medical records are not at the investigational site, it is the responsibility of 
the investigator to obtain those records if needed. 
13.4 Monitoring, Auditing, and Archiving  
13.4.1 Monitoring   
Before the start of the trial (i.e., before the inclusion of the first subject in the first center), the 
Investigators and the Sponsorâ€™s staff or a representative will meet at the site -initiation visit to 
discuss the trial protocol and the detailed trial procedures. Emphasis will be placed on inclusion and exclusion criteria, visit timing, safety procedures, informed consent procedures, SAE reporting procedures, CRF completion, and the handling of samples and products. The Sponsorâ€™s 
                                                
 
a  Unless the electronic medical records are managed by [CONTACT_35385] 
21 CFR Part 11, in which case they are acceptable on their own.  
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 73 of 80
[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 74 of 79 staff or a representative will ensure and document that all material to be used during the trial has 
been received at the site; and that the study investigator team and local Sponsor /delegate  staff 
have been properly informed about the trial, GCP and regulatory requirements, and the Sponsorâ€™s 
procedures. Specific training sessions for the study investigator team and the CRAs on these topi[INVESTIGATOR_35291], and should be documented. 
The following instruction manuals will be provided: the CRF Completion Guide lines  for entering 
data into the CRF, and the Operating Guidelines for detailed trial procedures such as the product 
management and sample-handling procedures. 
After the start of the trial, the Sponsorâ€™s staff or a representative will be in regular contact [CONTACT_125638]-up visits. The Investigator or delegate must be available for these visits, and must allow the Sponsor /delegate staff direct access 
to subject m edical files and CRFs. During these visits, the Sponsor/delegate staff will:  
â€¢ Evaluate the quality of the trial progress (adherence to protocol and any study- specific 
guidelines, quality of data collection and document completion, signature [CONTACT_35396], occurrence of SAEs, sample and product management, cold-chain monitoring, archiving) 
â€¢ Source-verify completed CRFs and any corresponding answered queries 
â€¢ Determine the number of complete or ongoing issues identified at monitoring visits (e.g., 
protocol deviations , SAEs) . Any identified problems will be discussed with the Investigator, 
and corrective or preventive actions will be determined, as appropriate. 
â€¢ After all protocol procedures have been completed and the data have been entered into the 
CRF, the In vestigator must still be available to answer any queries forwarded by [CONTACT_1034]. 
All data -related queries must be completed prior to database lock.  
At the end of the trial, a close-out visit will be performed to ensure that: 
â€¢ The center has all the documents necessary for archiving  
â€¢ All samples have been shipped to the appropriate laboratories 
â€¢ All unused materials and products have been either destroyed or returned to the Sponsor 
13.4.2 Audits and Inspections  
A quality assurance audit may be performed at any time by [CONTACT_1034]â€™s Clinical and Medical 
Quality Operations department ( C&MQO)  or by [CONTACT_357306], GCP and ICH requirements, and other applicable 
regulations. An inspection may be conducted by [CONTACT_12721]. The Investigator must allow direct access to trial documents during these inspections and audits.  
13.4.[ADDRESS_494862] keep all trial documents after the completion or discontinuation of the trial, 
whatever th e nature of the investigational center (private practice, hospi[INVESTIGATOR_307], or institution), for as 
long as required by [CONTACT_774]. In the absence of any applicable laws or regulations, trial documents will be kept at a minimum for the duratio n indicated on the Clinical 
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 74 of 80
[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 75 of 79 Trial Agreement (CTA). In no event, should study personnel destroy or permit the destruction of 
any trial documents  upon less than 90 days advance written notification to the Sponsor. In 
addition, trial documents should continue to be stored, at Sponsorâ€™ s sole expense, in the event that 
the Sponsor requests in writing that such storage continues for a period of time that exceeds that 
required by [CONTACT_357307] . The Investigator will inform [COMPANY_011] 
Pasteur of any address change or if they will no longer be able to house the trial documents. 
Archived data may be held on electronic records, provided that a back-up exists and that a hard copy can be obtained if required. The protocol, documentation, approvals, and all other documents related to the trial, including certificates attesting that satisfactory audit and inspection procedures have been carried out, will be kept by [CONTACT_35389] (TMF). Data on AEs are included in the TMF. All data and documents will be made available if requested by [CONTACT_190660].  
13.[ADDRESS_494863] and Insurance Coverage  
A CTA will be signed by [CONTACT_125639]â€™s performance, if relevant. The 
Sponsor has an insurance policy to cove r any liabilities that may arise from use of the product  
and / or the study protocol. 
13.[ADDRESS_494864]â€™s parent / guardian may be provided with a stipend according to local practice to compensate for the time and travel required for study visits and procedures.  
13.[ADDRESS_494865] 90  days prior to submission for publication / presentation. 
Any information identified by [CONTACT_125640], 
it being understood that the results of this trial are not to be considered confidentia l. 
[COMPANY_011] Pasteurâ€™s review can be expedited to meet publication guidelines. 
 
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 75 of 80
[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page [ADDRESS_494866] 
 
1 Granoff DM, Har rison LH, Pelton S. Meningococcal vaccines. In: Plotkin SA, Orenstein 
WA, Offit PA, editors. Vaccines. 6th ed. Philadelphia (PA): Saunders (Elsevier); 2013:388-
418. 
2 Harrison LH, Tro tter CL, Ramsay ME. Global epi[INVESTIGATOR_357248]. 
Vaccine. 2009;27(Suppl 2):B51-63. 
[ADDRESS_494867] Dis. 2013;19(4):566-73. 
[ADDRESS_494868] Dis J. 2004;23(12 Supp) :S274-9. 
5 Kvalsvig AJ, Unsworth DJ. The immunopathogenesis of meningococcal disease. J Clin 
Pathol. 2003;56(6):417- 22. 
[ADDRESS_494869] Dis. 2003;9(11):1486-8. 
7 World Health Organization. Meningococcal disease, serogroup W135 (update). WER. 
2001;76(28):213-4. 
8 Ibarz -Pavon AB, Gabastou J-M. Improving surveillance and characterization of 
meningococcal disease in Latin America and the Caribbean region: a collaborative research program for strengthening regional surveillance network based on laboratory evidence of N. meningitidis. Final Report 2010-2013. Available at URL: https://partners.sanofi.co m/global/menactra/Documents/PAHO%20SIREVA%202%20Meni
ngococcal%20Surveillance%20Final%20Report.pdf. Accessed [ADDRESS_494870] Dis. 2008;14(7):1089-96. 
10 Kilic A, Urwin R, Li H, Saracli MA, Stratton CW, Tang YW. Clonal spread of serogroup 
W135 meningococcal disease in Turkey. J Clin Microbiol. 2006;44(1):222-4. 
[ADDRESS_494871] 
Dis. 2010;16(2):348-9. 
[ADDRESS_494872] Dis. 2013;19(9):1496-9. 
13 Efron AM, Sorhouet C, Salcedo C, Abad R, Regueira M, Vazquez JA. W135 invasive 
meningococcal strains spreading in South America: significant increase in Argentina. J Clin Microbiol. 2009;47(6):1979-80. 
14 Weidlich L, Baethgen LF, Mayer LW, et al. High prevalence of Neisseria meningitidis hypervirulent lineages and emergence of W135:P1.5,2:ST-[ADDRESS_494873]. 2008;57(4):324- 31. 
[ADDRESS_494874] Oswaldo Cruz. 2007;102(6):773-5. 
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 76 of 80
[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 77 of 79 16 Boisier P, Nicolas P, Djibo S, et al. Meningococcal meningitis: unprecedented incidence of 
serogroup X-related cases in Niger. Clin Infect Dis 2007;44(5):657-63. 
[ADDRESS_494875] Dis 1999;180(6):1894-901. 
18 Canadian Immunization Committee and Public Health Agency of Canada. Advice for 
consideration of quadrivalent (A, C, Y, W135) meningococcal conjugate vaccine, for use by 
[CONTACT_167552] . CCDR. 2010;36(S2):1- 35. 
19 Broker M, Jacobsson S, Kuusi M, et al. Meningococcal serogroup Y emergence in Europe: 
update 2011. Hum Vaccin Immunother. 2012;8(12):1907-11. 
20 Cohn AC, MacNeil JR, Harrison LH, et al. Changes in Neisseria meningitidis disease epi[INVESTIGATOR_167491], 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis. 2010;50(2):184 -91. 
21 National Foundation for Infectious Diseases. Addressing the challenges of Serogroup B 
meningococcal disease outbreaks on campuses: A report by [CONTACT_394305]. May 2014. Available online: http://www.nfid.org/meningococcal-b. Accessed 23 February 2015. 
22 Centers for Disease Control and Prevention. Inter im guidance for control of serogroup B 
meningococcal disease outbreaks in organizational settings. Available online: http://www.cdc.gov/meningococcal/downloads/interim-guidance.pdf. Accessed 23 February 2015. 
23 European Centre for Disease Prevention and Control. Annual epi[INVESTIGATOR_154341] 2014 -
Vaccine- preventable diseases - invasive bacterial diseases. Stockholm: ECDC; 2015. 
Available online: http://ecdc.europa.eu/en/publications/ Publications/AER -VPD- IBD-
2014.pdf. Accessed 11 June 2015. 
24 Public Health England. Increase in endemic Meningococcal group W (MenW) ST-11 
complex associated with severe invasive disease in England and Wales. Health Protection Weekly Report. Vol 8 No 41 Published on: 24 October 2014. Available online: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/367588/hpr4114.pdf). Accessed 11 June 2015. 
25 TÃ¶rÃ¶s B, Thulin Hedberg S, Jacobsson S, Fredlund H, OlcÃ©n P, MÃ¶lling P. Surveillance of 
invasive Neisseria meningitidis with a serogroup Y update, Sweden 2010 to 2012. Euro Surveill. 2014;19(42):pii=[ZIP_CODE]. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=[ZIP_CODE]. Accessed 11 June 2015. 
26 Thulin Hedberg S, TÃ¶rÃ¶s B, Fredlund H, OlcÃ©n P, MÃ¶lling P. Geneti c characterisation of the 
emerging invasive Neisseria meningitidis serogroup Y in Sweden, 2000 to 2010. Euro Surveill. 2011;16(23):pii=[ZIP_CODE]. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=[ZIP_CODE]. Accessed 11 June 2015. 
27 The European Meningococcal Disease Society (EMGM). 11th EMGM Meeting, 18 -20 May 
2011. Ljubljana Slovenia. Poster P035, 037-040. 
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 77 of 80
[COMPANY_011] Pasteur MET43 
395 â€“ MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 78 of 79 28 Centers for Disease Control and Prevention. Active Bacterial Core surveillance (ABCs) 
Report: Neisseria meningitidis, 2013. Available online: http://www.cdc.gov/abcs/reports -
findings/survreports/mening13.html. Accessed 22 September 2015. 
29 Centers for Disease Control and Prevention. Update: Guillain -BarrÃ© syndrome among 
recipi[INVESTIGATOR_167493] --[LOCATION_002], June 2005-
September 2006. MMWR Morb Mortal Wkly Rep. 2006; 55(41):1120-4. 
30 Velentgas P, Amato AA, Bohn RL, Chan KA, Cochrane T, Funch DP, et al. Risk of 
Guillain -Barre syndrome after meningococcal conjugate vaccination. Pharmacoepi[INVESTIGATOR_357249]. 2012;21(12):1350-8. 
31 National Research Council. Diphtheria toxoid, tetanus toxoid, and acellular pertussis 
containing vaccines. In: Stratton K, Ford A, Rusch E, Clayton EW, editors. Adverse effects 
of vaccines: evidence and causality. Washington (DC): The National Academies Press; 2012. p. 557-8. 
32 Stratton KR, Howe CJ, Jo hnston RB Jr., editors. Adverse events associated with childhood 
vaccines; evidence bearing on causality. Washington (DC): National Academy Press; 1994. p. 67-117. 
33 Centers for Disease Control and Prevention. General recommendations on immunization:recommendations of the Advisory Committee on Immunization Practices (ACIP):MMWR. 2011;60(2):1 -60. 
34 Menactra [pack age insert]. Swiftwater, PA ([LOCATION_003]):[COMPANY_011] Pasteur Inc.  
35 Newcombe RG. Interval estimation for the difference between independent proportions: 
comparison of eleven methods. Stat Med. 1998;17:873-90. 
36 Newcombe RG. Two -sided confidence intervals for the single proportion: comparison of 
seven methods. Stat Med. 1998;17:857-72. 
 
 
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
               
MET43
395 â€“ MenACYW Conjugate Vaccine
Protocol Version 2.0
Page 78 of 80